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Τ he IPTS Report is produced on a monthly basis ­ ten issues a year to be precise, since there are no issues in January and August ­ by the Institute for Prospective Technological Studies 
(IPTS) of the Joint Research Centre (JRC) of the European Commission. The IPTS formally 
collaborates in the production of the IPTS Report with a group of prestigious European institutions, 
forming with IPTS the European Science and Technology Observatory (ESTO). It also benefits from 
contributions from other colleagues in the JRC. 
The Report is produced simultaneously in four languages (English, French, German and 
Spaiiish) by the IPTS. We fact that it is not only available in several languages, but also largely 
prepared and produced on the internet's World Wide Web, makes it quite an uncommon 
undertaking. 
Tide Report publishes articles in numerous areas, maintaining a rough balance between them, 
and exploiting interdisciplinarity asfar as possible. Articles are deemed prospectively relevant if 
they attempt to explore issues not yet on the policymaker's agenda (but projected to be there sooner 
or later), or underappreciated aspects of issues already on the policymaker's agenda. Tl)e multi­
stage drafting and redrafting process, based on a series of interactive consultations with outside 
experts guarantees quality control. 
■ 
The first, and possibly most significant indicator, of success is that the Report is being read. T/je 
issue 00 (December 1995) had a print run of 2000 copies, in what seemed an optimistic 
projection at the time. Since then, readership of the papei· and electronic versions has far exceeded 
the 10,000 mark. Feedback, requests for subscriptions, as well as contributions, have come from 
policymaking (but also academic and private sector) circles not only from various parts of 
Europe but also from the US, Japan, Australia, Latin America, N. Africa, etc. 
We shall continue to endeavour to find the best way of fulfilling the expectations of our quite 
diverse readership, avoiding oversimplification, as well as encyclopaedic reviews and the 
inaccessibility of 'academic journals. Tlie key is to remind ourselves, as well as the readers, that 
we cannot be all things to all people, that it is important to carve our niche and continue 
optimally exploring and exploiting it, hoping to illuminate topics under a new, revealing light for 
the benefit of the readers, in order to prepare them for managing the challenges ahead. 
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Ethical Issues in Research Evaluation 
Isidoros Karatzas, Evaluation Unit, DG Research, European Commission 
and S tephan ie J . B i rd , MIT 
E thics and evaluation are integral parts of the co­evolution of science, technology and science management and science policy. society, supported by education and joint The current political pressure for public learning. It is important that in this context, ethical accountability in research and the far­ evaluation does not simply become an additional 
reaching impacts and controversies generated by layer in a bureaucratic process, but stimulates full 
research (e.g., new technologies, genetics), brought utilization of existing competencies to produce 
about changes that facilitate increased stakeholder informed advice as input to decision­making, 
involvement and a possible rapprochement of the Essential to this process is that evaluators 
scientific community with the general public. themselves be trained to recognise the ways in 
which ethical values are embedded in the design, 
It is of primary importance, before trying to conduct and reporting of research and evaluation, 
analyse the interface between RTD (Research and These values can be more fundamental than the 
Technological Development) ethics and évalua­ societal values, goals and concerns that motivate 
tion, to agree on a set of definitions. In the context the funding of research or influence how its results 
of this special issue of the IPTS Report, ethics are used, because embedded values are usually 
(from the Greek efhos meaning custom, mores, unacknowledged and often unrecognised. The 
character) is taken to define a system of moral need to support adequate coverage of the ethical 
principles or values; a principle of right or good issues in evaluation, requires knowledge and 
behaviour in relating to others; and finally, the expertise that are currently not readily available, 
rules and standards of conduct binding the Training of "proto­professionals" in this area 
members of a profession. Evaluation ¡s a process (interface of ethics and evaluation) is necessary in 
by which the quality, implementation, target order not to appear to be treating ethical issues as 
relevance and impacts of RTD activities are "add­ons" to the evaluation process, 
investigated, interpreted and examined. 
As self­education and monitoring are 
important elements of the evaluation process, self­
regulation is paramount in the ethical conduct 
process. G. Toulouse supports the establishment 
These definitions provide the interface 
between evaluation and ethics. This interface 
combines the conduct of research and the ethical 
assessment of expected results and impact, with of an evaluation culture as a mechanism for self­
three major types of evaluation: accountability, regulation in scientific societies. A recent survey 
strategic input and in­depth analysis of a specific by AAAS (American Association for the Advance­
area. This article by A. Rip lays the foundation for ment of Science) found that 57% of US scientific 
discussion of a "third­generation" ethics, based on societies currently engage in or plan to engage in 
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activities to promote research integrity1. The same 
survey shows that, at present, there has been very 
little formal evaluation of the effectiveness of these 
initiatives, and considers that rigorous evaluation is 
essential in order for the scientists and the public to 
have confidence in the self-regulatory functions of 
the scientific societies. Evaluation methodologies 
and self-regulation codes of conduct should be 
seen as living processes, evolving and adapting to 
the changes in the environment, and openly 
discussed in order to benefit from varying 
experiences and interdisciplinary approaches. If 
the scientific community does not take a leading 
role in safeguarding good research practices, it is 
probable that non-scientist stakeholders will 
undertake this task. 
In a participatory democracy, public confidence 
in government research activities is also greatly 
dependent on accountability. Scientists and 
research managers who follow the day-to-day 
development of research and witness the benefits 
of scientific inquiry, are convinced that these 
activities are valuable. This intuitive conclusion is 
difficult to quantify in a meaningful way and may 
not be easily communicated to all stakeholders2. 
Political demands for the quantification of 
research results and impact catalysed a shift in the 
values and ethical context of research evaluation. 
S. Cozzens' article analyses this shift as it was 
shaped by implementation of GPRA (Government 
Performance and Results Act). In the new context, 
the evaluator is responsible not only to his/ her 
professional community and his/her clients, but 
also to other stakeholders: strategic planners, 
policy makers and especially the public at large. 
In this new role, the evaluator seeks a clear 
articulation and measurement of public benefit. 
Stakeholder involvement is sought in order 
to improve the effectiveness of policies. In 
P. Thompson's article, the process which highlights 
the input from research to policy is outlined using, 
as a case study, the food and agricultural 
biotechnology area. Rapid advances in this field 
have led to new interpretations of long-standing 
policies in food safety, environmental impact and 
animal health. The shifting ethical paradigm 
presented in S. Cozzens' paper is also apparent 
here: ethical bias can be hidden within evaluation 
methodology itself and through socio-economic 
impact assessment and risk quantification, can 
affect policy choices. Furthermore, as Thompson 
points out any evaluation of socio-economic 
impacts of RTD will be incomplete if it fails to 
recognise the potential for new technologies (e.g. 
biotechnology) to affect the fundamental nature of 
the world in ways that alter basic legal concepts 
(such as property rights). As a result, evaluation 
must also address the possibility of restructuring at 
the constitutional level. 
As in agricultural biotechnology, the res­
tructuring seems necessary and long overdue in 
the area of gene technology and ethics. The paper 
by D. Ibaretta and Α-K. Bock presents the third 
type of evaluation dealing with an in-depth 
analysis of a field. In this context, the evaluation 
and ethics interface contains issues relating to 
safeguarding good scientific practice, and the use 
and impacts of research results. The ethical 
assessment of research should then be carried out 
at three levels3. According to the opinion of the 
European Group on Ethics (EGE) these levels are: 
• the research project from the point of view of 
the modalities of implementation; 
• the declared aims of the research and the 
envisaged applications of the results; and 
• the possible uses and consequences, in the 
medium and long-term, of the results and their 
impact on individuals, the environment and 
society in general. 
Evaluation of the first two levels is currently 
undertaken in the EC Quality of Life Programme 
as outlined in the brief note by L. Cordier. 
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Concerning the third level, the EGE opinion 
outlines the necessity for stakeholder invol-
vement: "the ethical assessment is up against the 
complexity and unforseeability of all the possible 
uses and consequences of the results of research. 
This is all the more difficult in that it is bound up 
with conceptions of the future of society in ge-
neral. This ethical assessment is, therefore, more a 
subject for public debate and for national and 
Community socio-political bodies". In the third 
level, the ERA (European Research Area) initia-
tive4 proposes specific themes for action (ERA 
point 7, Area of Shared Values), including: 
• Organization of "Citizens' Conferences" at 
European level; 
• Strengthening of links between national and 
European ethics committees; 
• Opening up of national ethics committees to 
experts from other European countries; and 
• Comparison of criteria used in the national and 
European programmes with the prospect of 
convergence around common principles, 
while respecting diversity. 
The success of stakeholder involvement and 
the effectiveness of public debates will greatly 
depend on a number of important structural 
changes. Firstly, ethics and evaluation should be 
part of university curricula, sensitizing future 
researchers to the challenges they will face later in 
their careers. As R. Hollander argues in her note, 
this training should be extended to the teaching 
staff so that relevant codes of ethics become 
familiar. 
A second important change requires increased 
effort to improve communication with the 
stakeholders. This communication depends on a 
common language and a basic shared under-
standing which will require effort by scientists, 
educators and science journalists, as well as the 
stakeholders to bridge conceptual gaps. Poor 
communication of the actual science, coupled 
with a lack of scepticism on the part of the public, 
contributes to potential misapplication or abuse of 
science5. Moreover in order to critically evaluate 
research findings that are used to influence or 
support public policy, it is important: 
• To be aware that values are embedded in 
scientific research 
• To understand the ways in which values 
become part of science and 
• To be able to distinguish the nature and source 
of values in scientific studies 
The openness of the scientific community to 
discuss issues of their expertise with their 
colleagues and the stakeholders, plus the value 
shift of the role of the evaluators towards an 
extended audience, will bring about the necessary 
structural changes and facilitate the co-evolution 
of science, technology and society. 
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Ethics tends to be 
viewed primarily as a 
force acting in the 
name of humanity 
against the supposedly 
autonomous dynamics 
of scientific and 
technological 
developments 
Ethics, RTD and Evaluation 
Arie Rip, University of Twente 
issue: Ethical aspects are increasingly being invoked as important for society's assessment 
of new scientific and technological developments. RTD (Research and Technological 
Development) evaluations which not only address the management of programmes and 
the extent to which goals are achieved, but also consider impacts, should attempt to 
evaluate what has come to be called ELSI (Ethical, Legal, and Social Implications). 
Relevance: It Is not immediately obvious how RTD evaluators can handle ethical aspects. A 
better understanding of ethics in relation to RTD, and to scientific and technological 
developments more generally, is an essential precondition. 
introduction1 
­
he key step to incorporating ethical 
aspects in the evaluation of new scientific 
and technological developments is to get 
away from the prevailing, but misguided 
notion that ethics is a countervailing force, acting 
in the name of humanity, against the supposedly 
autonomous dynamics of scientific and technolo­
gical developments. This conceptualization auto­
matically gives the moral high ground to the oppo­
nents of a particular new development (for exam­
ple, modern biotechnology), while proponents 
defend themselves in terms of a general promise of 
progress to be realized.2 Controversies about new 
technologies reproduce this pattern. Proponents 
see resistance and attribute it to ignorance and 
emotions, while critics argue that it is not just 
promised performance, but also the societal rele­
vance or need that should be evaluated. We can 
perhaps have square tomatoes, which are easier to 
harvest by machines ­ but do we need them? This 
is the debate about the so­called "fourth hurdle", in 
recent biotechnology, but the point can be 
generalized: even if assessed as safe, the question 
of real societal advantage should be considered. In 
biotechnology, and for new developments in the 
life sciences related to genetics, reproduction, and 
modification of human life, there is now a "fifth 
hurdle": the impact on human values. Ethics is then 
called upon explicitly, as an ally. The ease with 
which the metaphor of "hurdles" is used shows the 
prevalence of a proponent­opponent storyline, and 
ethics is, almost by definition, on the side of the 
opponents. 
Second and third generation ethics 
One effect of the one­sided association of 
ethics with defence against new technology is the 
neglect of the ethical and socio­political aspects 
of how scientists and technologists continually 
(and positively) add to the "furniture" of our 
world. Philosophical reflection on this shaping of 
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our world is sorely needed. A related effect of the 
proponent-opponent storyline is the way it locks 
scientists and technologists into insider roles, 
where they define what is good for society In 
terms of their own limited projections. An intri-
guing example is the development of cochlear 
implants, which would give deaf people some 
hearing. The deaf community, however, saw this 
as undermining their way of life, and making them 
into second-class hearers, rather than having their 
own way of communication.3 
The current use of the terms "ethics" and 
"ethical aspects" is part of the problem, rather than 
a pointer towards a solution. Firstly, there is the 
confusion between ethics as a scholarly discipline 
and actual morality, values and work towards 
what might be called the "good life". Scholars in 
ethics analyse moral issues, but need not 
themselves hold or propound high moral values. 
Their contribution can be important, but not in the 
sense that they themselves are exemplary in 
taking moral positions. 
Legal and political debate and analysis, and 
the general questions of a "good" social order are 
important normative issues, which are not served 
by treating them as ethical issues. Seen from the 
perspective of impacts, new scientific and 
technological developments are open, often 
unstructured societal experiments, in which many 
actors with various perspectives participate, often 
without their consent. These are much larger 
issues than can be treated by traditional ethics, 
with its focus on individual action. 
At a European Workshop on Socio-Economie 
Impact Evaluation in Helsinki, November 1999, the 
Hungarian philosopher of science and technology 
Imre Hronszky called for a "third generation" of 
ethics. His starting point was the co-evolution of 
science, technology and society and the joint 
learning that is possible if one recognizes the open-
ended character of this co-evolution, rather than 
immediately trying to attribute praise and blame. In 
our knowledge society, which is also a risk society, 
reflection is possible, and competencies in such 
reflections can be and should be encouraged. For 
Hronszky, this means that ethics, in its third-gene-
rational form, is endogenized, as an integral part of 
the co-evolutionary dynamics. Actors other than 
professional ethicists and spokespersons for moral 
values would also be important, and RTD eva-
luators could play a role as well. 
Part of the notion of third-generation ethics is 
not to start by defining a moral high ground, but 
to discover it through a joint learning process. This 
approach is similar to recent developments in 
technology assessment (independent from the 
recent interest in ethical aspects).4 The co-
evolution and learning perspective mitigates the 
danger of over-simplified reference to given moral 
and societal norms and values, which would lead 
to fundamentalism, and in our present pluralistic 
societies, to mutual condemnation. But there is 
also the other danger of accepting anything and 
everything, and containing variety only through 
procedures (voting -and abiding by the outcome-
being one example). 
An important strand of second-generation 
ethics is cultural relativism. From this viewpoint, 
debates about ethical impacts come to be seen as 
cultural issues, to be resolved by mutual 
accommodation and/or compartmentalization. 
This is, for example, how primary education is 
organized in several countries, with its public and 
private schools and with its debates on curricula. 
Another strand in second-generation ethics is 
discourse ethics and other forms of procedural 
ethics, which have attracted a lot of intellectual 
attention recently because of the intractable 
debates around biotechnology. Issues of standing, 
of scoping and agenda-building, and of style of 
interaction then take precedence over substantial 
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An important strand of 
second-generation 
ethics is cultural 
relativism. From this 
viewpoint, debates 
about ethical impacts 
come to be seen as 
cultural issues, to be 
resolved by mutual 
accommodation and/or 
compartmentalization 
Tliere has been a 
traditional division of 
responsibility in which 
scientists and 
technologists produced 
new options, 
industrialists took them 
up, and society had to 
take care of the impacts 
The division of 
responsibilities is no 
longer acceptable. 
Scientists are now 
expected to anticipate 
impacts and 
foresee risks 
issues. The focus is on what constitutes a good 
debate, a good decision-making process, a good 
interaction. Questions about what constitutes a 
"good" life in our late-modern, technological and 
risk society can be addressed, but that is up to the 
participants. 
We need to build on the insights of second-
generation ethics and take a further step, whether 
we call it third-generation ethics or not. That is, in 
addition to procedural ethics and mediation and 
other attempts at conflict resolution, we should be 
concerned about division of responsibilities, 
which is a way to address social order and the 
good life without fully specifying what they 
should be. This is particularly important for the co-
evolution of science, technology and society and 
how these processes can be modulated. 
Sharing responsibility 
Impacts are co-produced, but responsibilities 
for impacts differ. The ambivalences are brought 
out well in Jerry Ravetz's aphorism: "Science takes 
credit for penicillin, but society takes the blame 
for the bomb." In general, one can speak of a 
division of responsibility, in the same way we 
speak of a division of labour in production, 
making up the social order. The traditional 
division of responsibility was that scientists and 
technologists produced new options, industrialists 
took them up, and society had to take care of the 
impacts, somehow. The 1933 World Fair in 
Chicago celebrated a century of progress, and 
took as its motto: "Science Finds - Industry 
Applies - Man Conforms." 
This division of responsibilities is no longer 
accepted for two reasons. First, anticipation of 
impacts is now expected (witness the rise of 
technology assessment), regulatory agencies are 
more pro-active, and actors, including scientists, 
can be criticized for not being concerned with 
possible impacts. The action of molecular 
biologists in the early 1970s to call attention to 
possible dangers of recombinant-DNA research, 
and to consider a moratorium on such research, 
was an important event, and set a precedent. 
Second, there are the new, and newly recognized, 
risks of long-term and often uncertain, but 
possibly considerable consequences of human 
activities, for example of low-level exposure to 
chemicals and radiation. Such new risks haave 
not been adequately addressed, because no one is 
responsible for them. But they are now recog-
nized, by the public, policy-makers, scientists, 
and even insurance companies, and there are 
attempts to define new responsibilities. 
The precautionary principle5 is one possible 
guideline in addressing new risks and one could 
look upon it as a macro-ethical stance. Its 
political, legal and economic aspects have been 
debated, and there is now some acceptance of it, 
at least in Europe. The responsibilities involved are 
larger than the drafting of regulations, however. It 
must be linked with the general idea that scientists 
are responsible for early warning, even if this is 
based on necessarily speculative theories and 
models. It is also linked with the recognition of 
the importance of interaction with old and new 
stakeholders and various publics. 
What we see here is an emerging "constitution" 
for our technological risk society. This is a de facto 
constitution in that it is not laid down by law, 
although elements may eventually find their way 
into laws and regulations. It can nevertheless be 
forceful in guiding action, just as cultural norms and 
values in all walks of life are forceful. Appraisal of 
such an emerging constitution is important, and 
social and political philosophy can make an 
important contribution. 
With this is in mind it will be clear that in-
cluding ethical aspects in RTD evaluation is not just 
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a matter of adding a further kind of impact, namely 
an impact on moral and cultural values. A variety of 
issues are involved, ranging from integrity of 
scientific research (as it is called in the USA) to 
societal debate, always against the backdrop of the 
broader issues of the co­evolution of science, 
technology and society. In this broader picture, 
RTD evaluation can be framed as the question how 
actual and emerging divisions of responsibilities 
­as part of the social order­ work out. If a division 
of responsibilities has become more or less 
articulated, or if it is specified as a goal, evaluators 
can check how well things have actually turned 
out. If not, they can still identify and assess what is 
happening in terms of evolving divisions of 
responsibilities. In both cases, their work helps to 
increase reflexivity in our late­modern societies. 
This is a process approach, and has not place in 
debates about the importance of one or another 
value. For some issues, there is general acceptance. 
For example the requirement of informed consent 
and the protection of privacy. In these cases RTD 
evaluators can check whether the rules were 
followed. Other issues are still open, and 
sometimes contested. Such questions can also be 
taken up in an RTD evaluation, but at arm's length. 
As it were in "boxes", where actors (directly or as 
reported by the evaluator) can have their say 
without their values being endorsed by the 
evaluator (other than identifying them as sufficien­
tly important to be mentioned). 
The substantial task that the evaluator 
can address is an appraisal of the evolving 
division of responsibilities. The current interest in 
science and governance supports the inclusion 
of such a task, and identifies important elements 
such as interaction with stakeholders and 
citizens. 
Conclusions 
As with the established interest in dissemi­
nation of research results and interaction with 
users of research, evaluators work on two levels: i) 
the actual tracing of dissemination, uptake by 
users, satisfaction, and ii) a general understanding 
of such interactions and roles which allows 
sensible collection of data and interpretation of 
what they mean. Such an understanding builds on 
professional competencies and experience. For 
the new task, competencies and experience may 
not yet be in place. Hiring an ethicist or a political 
philosopher as part of the evaluation team, 
however, is not an answer (or at best, only a small 
part of it). Given the recent interest of sociologists 
and political scientists in issues concerning the 
knowledge society and the risk society, and in 
interactive policy making, their competencies 
could play an important role. Many professional 
RTD evaluators have, in fact, a background in 
these scholarly fields. 
The evaluation of ethical impacts will stimulate 
a reflexive co­evolution of science, technology and 
society. Evaluators will then not only be pro­
fessionals who do a good job, but also intellectuals 
who are motivated by the possibility of contributing 
to the "good life". Æ 
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Evaluation in Science: an Antidote 
to Impunity 
Gérard T o u l o u s e , Ecole Normale Supérieure 
issue: Mastery of science, the integrity of the individual scientist, and the governance of 
scientific institutions, are three inter-related domains which are open to ethical appraisal. 
Experience shows that a culture of impunity tends to develop whenever structures or 
groups of people are left above or beyond evaluation. 
Relevance: Full advantage should be taken of existing or potential opportunities for the 
exchange of experience on ethics-related evaluation issues among academic institutions. 
This, however, must be accompanied by the fostering of a broader culture of evaluation. 
introduction: shared knowledge 
t is necessary to recognize that even within 
the restricted circles of the European scientific 
community a better quality of understanding 
between scientists remains desirable. In order 
to establish a corpus of common knowledge on 
which meaningful social debates and relevant 
actions can be based, the resources of scientific 
organizations within civil society (e.g. associations 
for the advancement of science) are also clearly 
important, and they should be strengthened at the 
European level. Moreover, "Ethics and RTD eva-
luation" is a central theme for the construction of a 
European Research Area1 and in order to be 
properly addressed, much effort will be required at 
many different levels, including all levels of 
education. Within this larger background picture, 
this article, within the limitations of space, focuses 
on a few topical issues about which pragmatic 
steps can be proposed. 
Against the culture of impunity 
It is because the 20th century has been so 
marked by contrasts, with an unbounded capa-
city for creation, and an equally boundless 
capacity for destruction, that the 21st century, 
drawing lessons from the past, will be the century 
of ethics, said French President Jacques Chirac. 
The 21st century may well come to be also 
considered the century of evaluation. It should be 
noted that the word "evaluation" contains the 
word "value", and for science it is important to 
remember that this should include moral values 
as well as others, such as economic values, costs, 
returns, etc. In retrospect, it seems clear that 
the emphasis on scientific objectivity and 
the moral neutrality of science was, consciously or 
unconsciously, self-serving (Garrett and Bird, 
2000). The claim that science is intrinsically 
innocent, and all the blame for evil consequences 
should be directed toward technical applications, 
is part of an attempt to draw a circle of perfect 
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The expression "culture 
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to imply an extension of 
individual assessment 
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scientific enterprise 
impunity around itself. Academic freedom and 
social responsibility go hand in hand. 
Towards a culture of evaluation 
Many scientists still ask: "Why has ethics 
become so fashionable nowadays in science?" 
Whereas the right question to ask should be: "Why 
were ethical considerations excluded for so long 
from scientific activities?" Indeed the time is ripe for 
innovation, emulation and international coope-
ration on ethics. We live in a period of transition in 
which a dynamic equilibrium has yet to be found, 
given that the advances of science and technology 
constantly raise novel problems. Along the way, it 
undoubtedly will be necessary to develop antidotes 
against possible abuses and perversions of ethics 
-there are parodies of ethics, just as there are 
parodies of justice, parodies of democracy, etc. 
One frequent objection is that ethical 
judgement in science is extremely difficult. It is 
indeed true that ethics is often concerned with 
conflicts of values and rationales, and hard 
dilemmas may be met. But science is not easy 
either; yet we manage to do it because we take it 
seriously. So the right question is not whether 
collective ethical reflection in science is easy, but 
whether we take it seriously. 
Finally, it must be readily admitted that ethics 
committees alone will not solve all problems; 
their action must be part of a broader culture of 
evaluation. 
The expression "culture of evaluation" is meant 
to imply an extension of individual assessment 
tasks (e.g. journal refereeing) into a broader en-
semble, encompassing other relevant dimensions 
of the scientific enterprise: the professional values 
and ethical standards of both the individual and 
the community, lessons drawn from past and 
experience from elsewhere, review of evaluation 
procedures, etc. Such an evaluation culture will 
evolve and mature, guided by an increasing awa-
reness of the full scope of the social responsi-
bilities of the scientific community. 
Transition to a culture of evaluation implies re-
ciprocal shifts in attitudes among both evaluators 
and those being evaluated. Ideally, evaluation will 
cease to be feared and resisted. Rather it will be 
recognized and sought after as an aid to the 
evolution of science. 
The scope of ethical appraisal 
Broadly speaking, three domains are open to 
ethical appraisal: 
• Mastery of science: bounds and tempo (relative 
speed of progress on various research frontiers); 
• Professional integrity of scientists (e.g. develo-
ping a scientific ethos which is unfavourable to 
misconduct, dubious practices, etc.); 
• Scientific institutions (governance, evaluation, 
collective responsibilities). 
The last item is no less relevant than the 
previous ones, but it is a domain in which there is 
considerable inertia. 
In 1997 two convergent reports were indepen-
dently issued, one on Ethics and scientific institu-
tions by the French Comité d'éthique pour 
les sciences (CNRS, 1997), the other on Safeguar-
ding good scientific practice by the German 
Commissison on Professional Self-Regulation (DFG, 
1997). Both illustrate the close overlap between 
ethics and evaluation, including the evaluation of 
and by scientific institutions: What is necessary (...) 
is that not only every individual scientist and scho-
lar, but especially the institutions of science -
universities, research institutes, learned societies, 
scientific journals, funding organizations - develop 
a consciousness of good scientific practice and 
apply it in their day-to-day activity. 
© IPTS, No.50 - JRC - Seville. December 2000 
T h e I P T S R e p o r t 
Sixteen detailed recommendations are listed in 
the German report, covering topics such as men­
torship, authorship, referees, funding, evaluation 
criteria, protecting whistleblowers, disclosure of 
conflicts of interest, treatment of allegations of mis­
conduct, etc. The European Science Foundation 
is currently working on the definition of a set of 
European standards (a European code of good 
scientific practice) based on the range of national 
experiences. 
Every university, institution of higher learning, 
research institute, scholarly society, and science 
academy should have an ethics committee, pro­
perly informed of what is being done at different 
levels: local, national, European, global (cf. 
UNESCO's World Commission on the Ethics of 
Scientific Knowledge and Technology ­COMEST). 
This would make it possible for individual 
scientists to be able to turn to a local ethics 
committee, in order to obtain adequate help and 
advice if needed. The composition of these 
committees should be balanced between dis­
ciplines, genders, ages and hierarchical positions 
and include not only scientists, but also lay­
persons such as journalists, artists and represen­
tatives of the associative sector. In the near future, 
temporary service in an ethics committee will be 
part and parcel of any scientific career. This spread 
of responsibilities is imperative in order to dispel 
concerns that a new caste of non­scientists will 
dictate what constitutes the responsible conduct 
of science. 
One country with concrete initiatives in the 
area of ethics is Norway. It has a set of national 
ethics committees, a programme of double 
doctoral training in science and ethics, a par­
liament­sponsored Commission on human values 
and a complex of institutions associated with the 
Nobel Institute of Peace. This offers a potential 
model for other countries which are confronted 
with similar issues. 
Concrete steps 
The 1999 Budapest World Conference on 
Science for the 21s* Century (the first such inter­
national gathering since the Vienna conference in 
1979), which was convened by UNESCO (United 
Nations Educational, Scientific and Cultural Orga­
nization) and ICSU (International Council for 
Science), achieved consensus on three major 
points: the importance of ethics in science; on the 
urgent need to recognize the important contribu­
tions and role of women in science; and, on new 
opportunities for increased cooperation between 
the natural and social sciences. Many debates 
revolved around the gap between developed and 
developing countries (UNESCO, 1999), schema­
tically referred to as the "North­South divide". In 
this regard, a noteworthy element was the 
influence of the Third World Academy of Sciences 
(TWAS), which did not exist at the time of the 
Vienna conference (the TWAS was created by 
Abdus Salamin 1983). 
In May 2000, the InterAcademy Panel on 
International Issues (IAP, comprising 80 acade­
mies of science) endorsed a suggestion by Bruce 
Alberts, president of the NAS (National Academy 
of Sciences, USA), to create an InterAcademy 
Council (IAC), modelled on the National Research 
Council, which has been the operating arm of the 
NAS for over eighty years. The purpose of the IAC 
will be "to facilitate the provision of advice and 
recommendations on issues of global importance 
for those organizations and governments formally 
requesting such an input". 
The IAC is of particular interest both because it 
is a new international organization that will be 
responsible for assessment, and because its 
creation may test the credibility of science 
academies as evaluators, since many of them, 
living on a legacy of prestige or power, are prone 
to resist any evaluative control over their own 
modes of operation. 
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If some IAC reports prove able to prevent mis-
guided or premature ventures, and to act as a 
sobering influence against the recurrent hubris of 
various military, industrial and political comple-
xes, this new advisory council will indeed serve 
an important purpose. Furthermore, the parity bet-
ween North and South academies, which has 
been instituted within the IAC structure, is also in 
itself a significant move, and a step forward In 
ethical terms. 
As frequently occurs in scientific matters, this 
initiative brings both risks and opportunities. 
Among the risks is that the most powerful players 
come to dominate the smaller ones (no doubt, 
some political and corporate interests expect that 
the weaker academies will be easily manipula-
ted). In this regard a key question is whether ethi-
cal concerns will be rejected out-of-hand, in the 
name of strict "scientific objectivity", or whether 
they will receive adequate attention. A crucial 
debate, moreover, will take place around the 
concept of the precautionary principle2. 
In order to meet these new challenges, pressure 
will increase for the renovation of the national 
science academies in Europe. It is to be hoped that 
the recent developments concerning the IAP and 
IAC will provide a decisive push for reform, so that 
all national science academies within Europe will 
become truly credible partners (Toulouse, 1998; 
1999). If European science has the legitimate ambi-
tion to be able to stand up and to speak up convin-
cingly on the world stage, a thorough process of 
internal reform is a prerequisite. 
The provisions contained in the European 
Research Area initiative provide a useful framework 
in this regard. It Is to be hoped that full advantage 
will be taken of these opportunities, especially with 
regard to the exchange of experience and the possi-
bility of cross-participation in relevant articles. Æ 
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Results Oriented Management: A New 
Ethical Context for Research Evaluation 
Susan E. Cozzens, Georgia Institute of Technology 
issue: Over the last decade there has been a sea change in research evaluation, leading 
to greater emphasis on results-oriented management. This shift has stimulated much 
comment from the technical viewpoint, but little from an ethical viewpoint. 
Relevance: As applied to research, the methodological elements of results-oriented 
management are not new. However, old methods are being combined In different ways, 
with different potential uses and implications for policy. 
introduction 
he Government Performance and Results 
Act of 1993 (GPRA) required all U.S. go-
vernment agencies to write strategic plans 
and to set and report on annual perfor-
mance targets using quantitative indicators. Similar 
legislation was put into effect during the 1980s and 
1990s in a number of parliamentary systems, in-
cluding Canada, New Zealand, Sweden, and the 
United Kingdom. Elements of the results-oriented 
approach have been incorporated into research 
evaluation in the European Union, and some close 
cousins have been adopted for university assess-
ment in several countries. 
Research evaluators, like all evaluators, carry 
responsibilities in three dimensions. First, they are 
responsible to their clients -to produce usable 
results-, next, to their professional communities -to 
produce competent results-, and finally, they are 
responsible to the public -to produce and share a 
growing base of knowledge about how government 
programmes work, including questions about whe-
ther and how they are serving the public interest. In 
the pre-GPRA configuration it was possible for U.S. 
research evaluators to be highly responsible to their 
clients and to their professional communities, but 
difficult for them to serve the public. Because of the 
emphasis on results and the requirement for stake-
holder consultation, however, the new framework 
gives evaluators new opportunities in this respect. 
Old systems 
In the pre-GPRA era, two different styles of 
research management had been established in 
federal agencies in the United States, one targeted 
and one untargeted. They were differentiated first 
and foremost by the specificity of their technical 
objectives. In energy research, for example, 
specific new technical options were explored. In 
agriculture, the aim was to improve farming 
practice. Such areas were often subject to formal 
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In the pre-GRPA era 
targeted and untargeted 
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specialized expertise of 
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has effectively protected 
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and the theory that 
underlies peer review 
tends to devalue 
assessments of 
completed research 
planning processes, and programme officers were 
responsible for demonstrating on a regular basis 
that the research supported was contributing to 
the objective. If it was not, the programme was 
changed to make it more likely to be effective. 
In contrast, at the National Institutes of Health 
(NIH), the goal was to advance fundamental un-
derstanding of biological processes underlying 
human health. Programmes supported fields of 
research that were relevant to medical problems, 
but seldom tried to press specific solutions. At the 
National Science Foundation (NSF), the untar-
geted approach went even further. The NSF sought 
to maintain the health of academic research, and 
supported excellent research in almost any field 
that needed fundamental explorations to balance 
mission-supported efforts. Both these agencies 
developed strong systems to let the research com-
munity itself determine which projects to fund 
through a strong peer review system. 
These two styles of management also developed 
distinctive programme evaluation practices, to fit 
the theory underlying their operations. Before the 
1990s, the fundamental research agencies commi-
ssioned occasional formal programme evaluations, 
primarily outside their core research activities. For 
example, the NIH carried out extensive data collec-
tion on its training programmes, and took a careful 
look at its international exchanges. The NSF evalua-
ted centres, women's programmes, and the explo-
ratory research efforts. Mission agencies, like the 
Department of Defense and the Department of 
Energy, by and large had systems of regular pro-
gramme review, in which outside evaluators were 
asked to provide an assessment of programmes 
based on information provided by the agency. 
Old roles 
Three professional communities were involved 
in these pre-GPRA evaluations. The first were 
evaluation staff, who were most often former 
researchers who took on management respon-
sibility after some time in government as research 
administrators. Second were the members of the 
research community who were recruited for eva-
luation panels. Third were the professional evalua-
tors, mostly non-academic contract research orga-
nizations plus a handful of academic researchers 
and small firms. 
The lines of responsibility from all three of these 
evaluator groups to agency management have been 
clear. Evaluation staff and contract researchers had 
to negotiate permission and resources from senior 
management for everything they did. The questions 
senior management wanted to have answered were 
the natural focus, and there was little room for 
experimentation. As for external reviewers, their 
independent judgement was 
valued and protected in the process. Agencies 
therefore tried to choose reviewers that understood 
their mission and context, so that any advice they 
received would stay on track. 
In the second area of responsibility, i.e. that to 
the professional community, the three groups diver-
ged. Staff and reviewers were both particularly tied 
to the research community. The scientific compe-
tence and judgement they brought to the process 
were highly valued. The professional evaluators, 
while not researchers in the fields being evaluated, 
nonetheless had the standards of their own me-
thods communities to answer to. They needed to be 
systematic and unbiased in the collection and 
presentation of evidence, to use the best methods 
available, etc. Since the research assessment com-
munity is quite small, and contracts are very com-
petitive, the quality control exercised through 
reputation is fairly strong. 
The third area of responsibility, i.e. to the 
public, presented the greatest challenge for all the 
pre-GPRA research evaluators. The challenge 
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began with the insulation of research programmes 
themselves from high levels of public attention. 
The specialized expertise of the research commu-
nity has effectively protected' it from close scru-
tiny, especially since the voting public is usually 
either neutral or positive in its views about 
research. Second, the theory that underlies peer 
review tends to devalue evaluations of completed 
research. There are no objectives in the traditional 
sense against which a basic research programme 
should be evaluated. Some evaluation staff there-
fore claimed in the pre-GPRA era that no one 
knew how to evaluate such a programme. Finally, 
the gradual narrowing of the performer base for 
research evaluations to the contract research 
organizations reduced the incentive to build 
a broader base of knowledge about how the 
research enterprise works. The result was that there 
was very little in the way of an empirically based 
discussion around alternative research policies. 
New systems 
The new accountability systems are distin-
guished by the need to be explicit about many 
matters that were implicit under the old system. The 
concept of excellence itself must be spelled out and 
made visible outside the research community. 
Because the new system stresses value to the pu-
blic, research evaluators are moving away from 
their close relationship with the research commu-
nity and toward a clearer articulation and measu-
rement of public benefit. Four emphases in these 
new frameworks work toward that end: results, 
indicators, stakeholder involvement, and strategic 
planning. 
Results. The new accountability systems 
demand that results be shown for money spent. 
Excellence involves producing something tangible 
and specific. For government laboratories and 
other targeted programmes, attention to results is 
part of their normal business. Regular progress 
reports provide information to management on 
what is coming out of the activities of the lab. 
Programme review uses that information to inform 
future activities. For the fundamental research 
programmes, however, the new demand for 
results is revolutionary. It is remarkable how little 
was known about the results of grants before this 
new movement, and equally remarkable how 
little the information that was available was used 
in management. The NSF can serve as an exam-
ple. This lack of concern with results was the flip 
side of the emphasis on maintaining excellence 
through competitive proposals and project 
selection through peer review. The NSF was very 
confident that what it had funded was the best 
available. This was fine under the old system for 
accountability. But under the new expectations, 
including those outlined in GPRA,'that confiden-
ce was not enough. The agency needed to show 
outputs and outcomes, not just a high level of 
quality control on inputs. 
Indicators. A second emphasis in the new 
accountability systems is the use of quantitative 
indicators. If the worth of a programme cannot be 
measured, so the philosophy goes, the programme 
itself cannot be managed. In the U.S., GPRA 
forced a critical examination of the numbers that 
were candidates for performance indicators. What 
were available were many kinds of input num-
bers, measuring levels of activity as they appear in 
management information systems. In fact, most of 
the indicators in most performance monitoring 
systems around the world are input indicators, 
derived from management information systems 
that pre-date accountability requirements. 
In the area of results indicators, publications 
could have been used as an output indicator. Not 
a single U.S. agency has chosen to do so. The U.S. 
university system has steered away from the use of 
publication counts as an evaluative measure, be-
cause it encourages quantity rather than quality. 
The new accountability 
systems are distin-
guished by the need to 
be explicit about many 
matters that were 
implicit under the old 
system. The four areas 
of emphasis are results, 
indicators, stakeholder 
involvement, and 
strategic planning 
Most of the indicators 
used in performance 
monitoring systems are 
input indicators. 
Among the possible 
output indicators, 
publication statistics, 
in particular, are 
avoided, given their 
tendency to place 
empliasis on quantity 
rather than quality 
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distortion of behaviour 
The new accountability 
systems require 
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vement. Excellence is 
now in the eye of many 
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whom report back 
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what they see 
The NSF consciously chose not to base perfor-
mance goals on output measures because of the 
possibility for distortion of behaviour. 
In the end, then, quantitative outcome mea-
sures - what GPRA seeks - are rare in the perfor-
mance reporting of U.S. research agencies, and 
appear primarily in the programmes at the 
technological end of the spectrum. Applied re-
search agencies have been able to do techno-
logical road-mapping of the paths toward their 
targets, and report on passing the milestones on 
the roadmap. Economic cost-benefit analysis 
appears in the report of the standards laboratories 
of the National Institute of Standards and 
Technology. Similarly, improvement toward speci-
fic technical targets is reported, for example, 
increasing the power of instrumentation in faci-
lities provided by the Department of Energy. 
Stakeholder involvement. The new accoun-
tability systems require stakeholder involvement. 
Excellence is no longer found only in the views of 
managers and the research community. Represen-
tative democracy has required that participatory 
democracy play a role. Excellence is now in the 
eye of many beholders, all of whom report back to 
legislators on what they see. 
A role for external stakeholders had been 
growing in the research enterprise for some time 
before the new accountability systems were put in 
place. The first set of stakeholders welcomed into 
the system were from industry, through coope-
rative programmes and centres; and they are still 
the numerically most dominant group. The new 
accountability systems have encouraged a genera-
lization of stakeholder involvement, however, 
beyond industry. In the U.S., for example, state 
and local governments are often brought into the 
decision processes around research, and some-
times schools are as well. NGOs are also beco-
ming frequent participants in these processes, for 
example, when environmental groups participa-
ted in the U.K. Foresight exercise. When govern-
ment laboratories and funding programmes 
develop the knowledge base for regulatory deci-
sions, it is important to include users from govern-
ment departments in the research management 
process. 
Strategic planning. Last, but by no means least, 
the new accountability systems require strategic 
planning. Many government organizations had 
not done this before, and quickly discovered the 
challenges of trying to make sense of the mis-
cellany of functions they had been given by 
legislatures over the years. In the U.S., applied 
research organizations, including most govern-
ment laboratories, have responded well to this 
demand and developed and refined long and 
short-term strategic goals that are being translated 
effectively into performance goals. For example, 
the National Océanographie and Atmospheric 
Administration has performance goals for impro-
ving the lead-time and accuracy of predictions of 
severe weather conditions. For example, they 
want to increase the lead time in predicting flash 
floods from 41 minutes to 57 minutes, and in-
crease accuracy to 85%. These goals are of ob-
vious benefit to the public, and give a clear target 
for organizing research efforts. 
There is still a great deal of ambivalence in the 
research community about the value of strategic 
planning, especially in fundamental research, 
where there Is general agreement that roadmaps 
are not possible. Yet there are positive results from 
the process. First, it has sharpened understanding of 
goals and audiences, even in basic research pro-
grammes. Strategic plans do this by introducing a 
refined language of goals, and making it part of 
discussion in the everyday life of the organization. 
The first teams to use the new system at the NSF 
were forced into a serious discussion of who the 
audience was for the field (beyond the researchers 
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themselves), and the best ways to reach that 
audience. Before GPRA, such teams would have 
been taken up with an audit of the project selection 
process, and never asked about either audiences or 
results. 
Second, strategic planning is transforming 
basic research into strategic research. There is a 
(possibly apocryphal) quotation about basic 
research from Werner von Braun: "Basic research 
is what I'm doing when I don't know what I'm 
doing." There is no room under the new accoun-
tability systems not to know what you are doing. 
Even basic research needs its public justification. 
At the NSF, for example, we discovered under 
GPRA why we were supporting astronomy: kids 
get excited about science through astronomy, and 
getting kids excited about science is good for the 
country. Surely, this process of specification is 
good for the enterprise. 
New roles and responsibilities 
While the evaluator's responsibilities to clients, 
professional communities, and the public have 
changed under this system, the three groups are 
still involved, and in somewhat similar 
relationships to one another. However, the key 
change is that some new groups are also included, 
and a much broader and higher level of attention 
to their input is required. 
The new groups include the stakeholders for 
the programmes (who must be involved in the 
strategic planning process under the terms of the 
Act) and the Congressional audience. These two 
groups represent the public in ways that are signi-
ficantly stronger than the delegation patterns of 
the old systems. They form an active audience for 
results from the assessment system, an audience 
that goes above the heads of the senior agency 
management who were the primary clients 
before. Those agency heads are still an important 
part of the picture, but now they do assessment by 
requirement, not just by choice, and the assess-
ment results must be reported outside the agency 
in the form of performance indicators. 
The policy and planning staff who commissio-
ned special evaluation studies in the old system 
and organized external review panels are still acti-
ve and central players under the new systems, but 
budget offices have become an important group of 
partners and clients in the enterprise, and policy 
and planning staff have the added responsibility of 
getting programme staff from across their agencies 
to "buy in" to the system adopted. Adding all these 
additional players has made the lives of planning 
and policy offices much more complicated. 
Many research agencies have looked to peer 
review processes to address the GPRA puzzle. The 
review panels are thus still involved, and in fact 
play a more central role in the new systems 
because their results have a Congressional as well 
as agency audience. They must make judgements 
that can be publicly available, and they know that 
their judgements can have an impact on resources 
for the agency that has chosen them. From the 
agency viewpoint, the panel solution fits the 
ideology of peer review, and invokes the 
established protection of "special expertise" that 
insulated research for so long from close public 
scrutiny. However, there is an underlying issue 
that has barely been broached in the discussion 
around the use of peer panels for GPRA: conflict 
of interest. The conflict of interest problem is 
solved in project selection processes by having an 
individual with a conflict on a specific proposal 
leave the room while it is discussed. However, the 
conflicts of interest in programme evaluation run 
much more broadly and deeply than the narrower 
rules acknowledge or address. Almost everyone 
who is likely to be technically competent to serve 
on a panel at research programme level also has a 
stake in seeing the field supported. 
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Agencies will need 
help with involving 
stakeholders in strategic 
planning, developing a 
model of the logic of 
their programmes, 
and translating new 
concepts of outputs and 
outcomes into measures 
Finally, while in theory GPRA could have pro-
vided an increased level of activity for professio-
nal evaluators, in practice, at least in research, it 
has not. The law assumes that agencies are enga-
ged in regular programme evaluation, and requi-
res that agencies provide a schedule of their 
programme evaluation activities. But designing an 
indicators system is quite a different task intellec-
tually than designing a good programme evalua-
tion, and agencies have been taken up with the 
difficulties and costs of GPRA implementation over 
the last five years or so. 
Ultimately, the work that will be generated for 
professional evaluators under GPRA will come 
from its incorporation into standard practices 
within the many parts of agencies. Agencies will 
need help with involving stakeholders in strategic 
planning, developing a model of the logic of their 
programmes, and translating new concepts of 
outputs and outcomes into measures. The new role 
for professional evaluators is to facilitate those pro-
cesses, rather than to carry out set-piece evalua-
tions. This move makes it easier for the professional 
evaluator to be responsive to the three groups 
indicated earlier. The client is closer, and more 
directly involved in absorbing the results of the 
process, so the results feed more directly into his or 
her decision making. As with the earlier set of skills, 
a professional community of evaluators sets the 
standards for quality in this work. Finally, because 
stakeholders are more closely involved, there can 
be a greater sense of direct public responsibility. 
Conclusions 
In summary, then, the new approach stresses the 
responsibility to provide value to the public. As a 
result, the new environment has produced a new 
configuration of roles and responsibilities for the 
groups involved in the research evaluation process. 
Research evaluators are moving away from their 
close relationship with the research community 
and toward a clearer articulation and measurement 
of public benefit. The professional evaluator can no 
longer sit in an office, setting up and carrying out 
pristine research designs and writing elegant 
reports that may or may not get read. Instead, the 
new research evaluator needs a new set of skills, 
like facilitating strategic planning, which helps 
organizations articulate their goals; stakeholder 
involvement, which reaffirms the role of the public; 
and logic modelling, to clarify how programmes 
bring about their results. Knowledge of methods is 
still necessary since the model of programme logic 
will ultimately need to be translated into indicators, 
in an efficient way that speaks in simple language 
to non-experts. Yet the new world also calls for 
better knowledge of management practices and 
issues, and a greater sensitivity to the Congressional 
context for a programme. 
This new context holds significantly more 
promise for allowing issues of public service and 
public interest to surface in the assessment process, 
on a case by case basis. If the potential of G PRA for 
achieving this change is fulfilled, it will have lived 
up to its name and indeed achieved results, j 
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Food and Agricultural Biotechnology: Ethical 
Issues Behind Research Policy Choices 
Paul Thompson, Purdue University 
issue: Food and agricultural biotechnologies have demanded new interpretations of 
longstanding policies in food safety, environmental Impact and animal health. The 
controversy over agricultural biotechnology reveals a number of ethical concerns in 
existing approaches to agricultural research evaluation. 
Relevance: Ethical issues might be raised with respect to many types of technology. An 
overview of the controversies associated with agricultural biotechnology provides a 
microcosm for understanding a key set of ethical issues associated with any attempt to 
evaluate research and technology development, or to use such evaluations In research 
management policies. 
introduction 
A n important issue in science today is the tension between research policy, which stresses optimal trade-off of risk and be-nefit, and policy that aims to satisfy 
criteria of informed consent. A second major 
issue concerns the role of agency and intention 
in making research choices, and questions of 
responsibility for both intended and unforeseen 
consequences. A third concerns the appropriate 
role of uncertainty and precaution in research 
evaluation and planning. A fourth concerns the 
socio-economic impact of agricultural biotech-
nology on the viability of farms, rural commu-
nities and the process of globalization. 
The agricultural sciences present a particularly 
interesting case study for examining ethical issues 
in technology evaluation, and especially so with 
respect to the products of gene transfer. Worldwide, 
agricultural research has been organized and 
conducted by public institutions such as national 
and international research centres and government 
funded university scientists for over 100 years. 
Agricultural research has, from the outset, been 
highly applied, aimed at discoveries and techno-
logy development that would lead to improve-
ments both in food and fibre production, and in 
rural quality of life. Furthermore, agricultural 
technology and its socio-economic effects have 
been extensively studied by social scientists for 
many decades. Although this research has not been 
undertaken within the framework of officially 
mandated evaluation activities, it has been con-
ducted in a variety of national settings, has de-
ployed many social science research methods, and 
has examined a wide range of issues. 
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Given this knowledge base, research adminis­
trators approached the development of new 
agricultural and food technologies using techni­
ques for mapping and transferring genes from one 
organism to another with a high degree of confi­
dence in their ability to prospectively select appro­
priate topics for research. Given the controversy 
and chaos that greeted the products of food and 
agricultural biotechnology, it is apparent that their 
confidence was somewhat misplaced. Neglect of 
ethical issues, both in the evaluation of agricul­
tural research and In the policy decision making 
that was based on the social science literature 
extant in the 1980s when many key decisions 
were made, is one of the key elements in 
accounting for this failure. 
Agricultural science and technology 
evaluation 
As noted, agricultural science and technology 
have been subjected to social Impact evaluation for 
several decades. This research is based on 
economic simulation models developed primarily 
for monitoring and predicting price and quantity 
performance of the agricultural sector for both 
developed and developing country economies. 
Many agricultural technologies lend themselves to 
estimation of impact on commodity yields, and 
data on farmer adoption rates and reported yields 
allow these estimates to be incorporated into 
agricultural sector models. Beginning in the 1960s, 
these basic models began to be augmented with 
techniques to evaluate negative externalities attri­
butable to environmental impact and social dislo­
cation. A number of the key papers in this literature 
are collected by Berardi and Geisler (1984). 
Beyond this sketch, the evaluation literature on 
agricultural science is too broad to summarize in 
this context. Vernon Ruttan's book Agricultural 
Research Policy (1985) provides an overview, and 
Rossmiller's Agricultural Sector Planning (1978) 
describes an interdisciplinary methodology for 
identifying research needs and implementing a 
participatory system for continuous evaluation of 
research impact. More recent publications by 
Huffman and Evenson (1993) and the U.S. 
Department of Agriculture Economic Research 
Service (1995) update this literature. Johnson and 
Bonnen's 5oc/a/ Science Agricultural Agendas and 
Strategies (1991) collects essays by many of the 
world's leading agricultural researchers summa­
rizing what is known and what needs have yet to 
be met regarding the evaluation of agricultural 
and food systems performance. 
Existing agricultural sector models provide a 
number of ways for analysts to disaggregate the 
various influences on system performance, and to 
make defensible judgements about the relative 
influence of various contributing causes, including 
scientific and technological innovation. Given 
some plausible assumptions, models designed to 
predict agricultural sector performance with 
respect to commodity prices and environmental 
externalities can serve as a basis for technology 
evaluation. First, one must assume that under the 
conditions of competitive markets, gains to 
agricultural producers orto food consumers (in the 
form of lower food prices) represent beneficial 
outcomes. Second, one must assume that it is 
possible to compare such beneficial outcomes with 
negative outcomes in a manner that adequately 
reflects all the parameters that are relevant to the 
evaluation process. Despite the initial plausibility 
of these assumptions the experience with agri­
cultural biotechnology reveals several areas of 
weakness. 
First, economic and sociological methods in 
use prior to 1980 were almost exclusively focused 
on a utilitarian or consequentialist model of tech­
nology evaluation, and provided decision makers 
with little insight into the way that science and 
technology could raise ethical issues relating to 
Χ* 23 Λ 
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rights and consent. This problem became par­
ticularly evident with respect to the way that con­
sumer interests were neglected in evaluating the 
use of rDNA techniques to produce genetically mo­
dified (GM) foods. Second, these methods were so 
strongly focused on outcomes that they neglected 
the way that the motives and moral character of 
actors would be used to evaluate the acceptability 
of products and the credibility of information 
regarding biotechnology. 
A third weakness concerns the environmental 
risks of genetically engineered crops, and a fourth 
involves the effect of genetic engineering on the 
socio­economic structure of farming and rural 
communities. These two weaknesses are surprising 
in that social science research on agricultural inno­
vation provided ample reason to expect that en­
vironmental impact and social consequences 
would be sources of controversy. One might 
conclude that decision­makers simply ignored the 
lessons from previous evaluations of agricultural 
technology. On the contrary, however, with respect 
to both environmental and social consequences, 
the way in which evaluation information is 
conceptualized can presuppose a particular ethical 
orientation. The current social controversy over 
agricultural biotechnology can be traced to a so­
mewhat narrow way of understanding the ethical 
significance of the evaluation process (Thompson, 
1997a). 
Optimization vs. consent 
Prior to 1980, virtually all of the social science 
research on the evaluation of agricultural research 
had an implicit ethical orientation toward what 
philosophers would characterize as utilitarian or 
consequentialist thinking. In this model, scientific 
research and technology development is impli­
citly understood as an initiating event that causes 
a variety of effects on human, animal and environ­
mental health, the economic well­being of 
individuals, and on aggregate socio­economic 
indicators such as GDP, distribution of income, 
national budgets, balance of payments and the 
like (Thompson, Ellis and Stout, 1991). As Barré 
(1999) points out, the methodological challenges 
in modelling the complex social mechanisms that 
mediate this causality, and in measuring these 
impacts, can be overwhelming. However, in this 
context, it is more important to highlight the nor­
mative presumptions involved in this conceptua­
lization of evaluation. 
The key idea is that each impact of research, as 
characterized above, can be understood as having 
beneficial or detrimental effects on social or indivi­
dual welfare. Investments in science and techno­
logy should promote beneficial impacts. Given the 
likelihood that there will be few instances of 
unalloyed benefits, research administrators should 
be sure that benefits outweigh detrimental outco­
mes, and should regard research investment as a 
process of seeking the best possible ratio of 
beneficial to detrimental outcomes. This norm is 
commonly expressed in terms of seeking the best 
ratio of benefit to cost. It derives from John Stuart 
Mill's statement of the utilitarian maxim, which 
states that the action that is ethically justified is the 
one that achieves "the greatest good for the greatest 
number." 
Agricultural biotechnology was subjected to a 
great deal of prospective evaluation research using 
a decision model suggested by the utilitarian 
maxim. Milton Hallberg (1992) produced a volume 
of essays reviewing the extensive evaluation 
literature on just one product of biotechnology, 
recombinant bovine somatotropin. Since risks to 
food consumers were judged to be very small, and 
benefits in the form of lower food prices were 
estimated to be significant, the acceptability of 
biotechnology to food consumers was never taken 
to be an important criterion in ex ante evaluations. 
As is now well documented, however, even con­
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sumers who expressed interest in trying GM foods 
were deeply resentful of a marketing approach that 
denied them the opportunity to give or withhold 
consent. Even consumers who thought of them-
selves as potentially benefiting from GM foods 
nevertheless insisted upon the right to decide for 
themselves whether to eat them or not (see Durant, 
Bauer and Gaskell, 1998). 
This should be seen as an ethical flaw not in the 
sense that anyone in agricultural research planning 
or evaluation wilfully acted unethically. Instead, the 
utilitarian orientation of the model being used to 
conceptualize the evaluation process had blind 
spots with respect to issues of coercion, consent 
and rights. The weakness of utilitarian thinking with 
respect to such issues has been recognized for 
many years. Although it may be possible to adapt 
consequence-evaluating social science research 
models to more accurately reflect the Importance 
of consent and rights, it may be easier to 
conceptualize the issues of rights and consent as 
distinct elements of the evaluation process. That is, 
in addition to evaluating the causal effects of a 
research programme, evaluators should ask how 
the research (or its expected products) could affect 
the rights held by affected parties prior to the 
implementation of a new technology. If rights will 
be affected, the burden on research administrators 
is to make a good faith effort to secure the parti-
cipation and consent of affected parties, rather than 
simply to convince themselves that the expected 
benefits of the research outweigh its costs (see 
Thompson 1997b; 2000). 
intentions, interests and motives 
A second weakness of standard utilitarian 
research evaluation is that in looking so Intently at 
the future consequences of a research activity, it 
tends to neglect the past. However, in the ethical 
evaluation of human action, the things that lead 
up to an action can be much more important than 
the consequences that follow it. In particular, the 
intentions, interests and motives of the agents who 
perform actions make all the difference in deci-
ding whether certain acts are right or wrong. One 
act of pulling the trigger may be heroic or forgi-
vable while another is murderous, and an analysis 
of the consequences involved in either case may 
not be particularly sensitive to the difference 
between the two. 
With respect to agricultural biotechnology in 
the 1980s and 1990s, the primary actors appear to 
have been positioning themselves to control and 
dominate research on seeds and agricultural 
technology well into the future. Certainly the 
commercial firms such as Monsanto, Novartis and 
Dupont have expected to profit from their 
research activities, but there have been arguments 
that their activities extend well beyond simple 
profit seeking into more extensive attempts to 
control the food and agricultural system. Further-
more, while one expects commercially funded 
research to meet the test of profit, the new agri-
cultural biotechnologies have been accompanied 
by a growing recognition of the way that profit-
seeking motivations may affect research policy in 
the publicly governed research sector, too. These 
developments may have undermined the credi-
bility of key actors in the agricultural biotechno-
logy arena. 
Barré (1999) calls for more descriptive atten-
tion to the networks of actors involved in research 
and development, and agricultural biotechnology 
may provide a case in point. With a few excep-
tions, agricultural research evaluation conducted 
prior to 1980 was largely inattentive to the inte-
rests, intentions and motives of actors. Even when 
it was attentive, it was infrequently integrated into 
prospective evaluations of agricultural biotechno-
logy in a manner that would have helped research 
administrators appreciate the way in which 
evolving industry-public sector research relation-
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ships might compromise the acceptability of the 
technology in the future. As with respect to con-
sent, the reason for this is at least arguably to be 
found in the limitations owing to the utilitarian 
bias of the primary social science instruments for 
conducting and communicating the evaluation of 
agricultural research. 
Environmental risks of agricultural 
biotechnology 
The environmental consequences of agricultural 
biotechnology have been hotly contested ever 
since the first field tests for genetically engineered 
ice-nucleating bacteria were proposed in the early 
1980s. As such, research administrators, planners 
and evaluators could not have overlooked the need 
to assess environmental impact. Furthermore, the 
utilitarian approach to evaluation of research is 
certainly capable of incorporating evaluation of 
environmental impact. Although the technical spe-
cification of environmental risk can become quite 
complex, risk is treated as an expected value in 
most utilitarian or consequential approaches to 
evaluation. Under the expected value approach, 
detrimental outcomes are evaluated probabilis-
tically, and the risk of a technology is rendered as a 
function of probability and degree of harm. 
The expected value interpretation of risk 
suggests two related strategies for coping with the 
unintended environmental consequences of tech-
nology. One is to treat risks conceptually as forms 
of cost, which are then subjected to cost-benefit 
style optimizing. In one sense there is nothing 
unique about environmental consequences, since 
in standard cost-benefit analysis virtually all costs 
and benefits are probabilistic in nature and are 
modelled for evaluation as expected values. Ho-
wever, environmental costs are thought to exhibit 
characteristics that make them differ from straight-
forward costs borne directly by producers and 
consumers in that benefits of reducing environ-
mental risks and costs are public goods. As such, 
standard markets do not provide incentives for 
reducing environmental risks and costs. 
The upshot is that when risks are interpreted as 
expected values, unintended environmental conse-
quences are understood as regulatory problems. 
Government regulatory agencies evaluate environ-
mental impact and regulate markets so that public 
benefits of reduced pollution and environmental 
damage are realized. This general approach was 
accepted by both public and private research enti-
ties undertaking product development of agricul-
tural biotechnologies in the 1980s and into the 
early 1990s (Bosin, 1990; Townsend, 1993). 
However, the evaluation of environmental risk was 
also conceptualized as an essentially technical 
activity, rather than one in which ethics would play 
a role. In this respect, the utilitarian presumptions 
of the prevailing approach to agricultural research 
and technology assessment may have led decision 
makers astray. By 1999, public confidence in regu-
lators' ability to address environmental risks of agri-
cultural biotechnology had fallen considerably 
(Durant, Bauer and Gaskell, 1998). 
The underlying ethical issue concerns the 
appropriate standard to apply in evaluating possi-
ble environmental impact. In moving immediately 
to a characterization of risk in terms of probability 
and degree of environmental harm, the expected 
value orientation of the utilitarian evaluation model 
militates against a precautionary mode of decision 
making. In the precautionary model, uncertainties 
are given precedence over what is known about 
possible benefits and costs; environmental risk is 
not characterized in terms of known potential 
outcomes and their measured probability of 
occurrence. In comparison with a predilection for 
choosing the optimal trade-off between cost and 
benefit, the precautionary stance is considerably 
more open-ended. As an approach to evaluation, it 
takes pains to present evaluative information in a 
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way that does not lead the audience to presume 
that known risks should be the basis for decision, 
rather than unknown risks. In doing so, it leaves 
open the possibility that a non-comparative, non-
optimizing criterion for addressing environmental 
impact may be the appropriate one for decision-
makers to use in a given situation (Ticknor, 1999). 
Social consequences of agricultural 
biotechnology 
Based on robust studies of previous agricul-
tural technologies, social scientists were quick to 
predict that agricultural biotechnology would be a 
contributing factor in the restructuring of agricul-
ture, the continuing decline of small-scale family-
operated farms, and the concentration of econo-
mic power among a few agribusiness firms (Kalter, 
1985; Kloppenburg, 1985; Kenny, 1986). These 
predictions precipitated several years of heated 
debate in the United States, mostly focused on the 
acceptability of social consequences associated 
with recombinant bovine somatotropin. Some 
argued that benefits to consumers counterbalance 
social costs incurred by farmers and rural commu-
nities (Tweeten, 1991). Others argued that these 
social consequences should be regulated in much 
the same ways as public health and environmen-
tal impact (Lacy and Busch, 1991). The issue was 
effectively decided in the United States when a 
1994 executive report concluded: "At no time in 
the past has the Federal Government prevented a 
technology from being adopted on the basis of 
socio-economic factors," (U.S. Executive Office of 
the President, 1994, pp. 35-6). 
There is an implicit ethical orientation to the 
U.S. Government's approach to social consequen-
ces. It is that social consequence debates revolve 
around the issue of distributing the costs and 
benefits of biotechnology. By not intervening in 
market mechanisms that influence producers' 
decisions to adopt or reject technology, U.S. 
Government policy permits the productive resour-
ces to be allocated according to market forces 
governing capital investments. Ethical and politi-
cal debate about the distribution of wealth in 
society is then focused on redistributive tax policy 
and entitlement programmes. It is difficult for 
government agencies to manipulate complex 
capital investment and producer decision making 
in a predictable fashion, and since private firms 
make these decisions, the public interest in the 
outcome of producer decision making may not be 
immediately obvious. In contrast, taxation and 
entitlements are debated in a political forum that 
is more obviously related to distributive justice. 
Furthermore, the U. S. consensus predilection for 
capitalism over centralized planning in the 
production sectors of the economy militates 
strongly in favour of this approach. -
This argument would be persuasive were it not 
for the fact that technological innovations can 
result not only in restructuring that reflects 
production efficiencies and the distribution of 
wealth, but also in a transformation of capabilities 
that is equivalent to a redefinition of basic 
constitutional rights, (Winner, 1983). The system 
of property rights in effect at any given time 
reflects a social and legal consensus on rules for 
access, control, exchange and the right to profit 
from use of goods, but it also reflects basic physical 
and biological capabilities with respect to the 
goods in question. Legal systems of property rights 
include stipulations about the right to transport 
portable goods, for example, but not for parcels of 
land or bodies of water because these are, by their 
very nature, permanent fixtures of a given lands-
cape. However, technological innovations in bio-
technology have effectively disaggregated traits 
(such as specific plant or animal characteristics or 
in the case of the so-called Terminator gene, 
biological reproductive capacity itself) so drama-
tically as to have vitiated property rights that 
farmers would have once held in seeds or animal 
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breeding stock. As such, it is doubtful that the old 
social consensus on rules for property exchange 
and capital investment in agricultural production 
can simply be carried over into a post­biotechno­
logy world without opportunity for renegotiations 
and political debate (see Kloppenburg, 1988). 
Clearly, the economic, political and sociolo­
gical issues that would bear on such a debate are 
complex, and any adequate discussion of them is 
far beyond the scope of the present article. The 
relevant point is simply that evaluation of socio­
economic consequences of science and techno­
logy will be incomplete if it fails to address the 
possibility of restructuring at the constitutional 
level. This is, arguably, a point that has either been 
overlooked or repressed in the last decade of 
debate over the social consequences of agricultu­
ral biotechnology. 
Conclusion 
Perhaps the most obvious need for ethics in the 
evaluation of socio­economic impact from scien­
tific research and technological innovation is 
simply that scientific integrity demands a fair and 
truthful evaluation process. To casual observers, it 
may seem as if ethical evaluation demands little 
more than rigour and honesty on the part of 
evaluators. However, the case of agricultural 
biotechnology indicates that there are a number 
of ways in which ethical bias can be hidden 
within evaluation methodology itself. Even those 
analysts who strive assiduously for objectivity can 
produce evaluation studies that fail to identify 
issues where the end products of scientific 
innovation create problems with respect to 
individual consent, or the intentions and conduct 
of key actors. Methodologies that presume a 
particular approach to the quantification of risk 
may neglect or conceal ethical issues that emerge 
when a precautionary approach is seen as the 
alternative to risk­benefit trade­off optimization. 
Assessment methodologies may also conceal 
the deeper significance of socio­economic conse­
quences when they are represented solely as issues 
in distributive justice. j | 
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Medical Uses of Gene Technology: 
Ethical and Social Concerns 
Dolores Ibarreta and Anne­Katrin Bock, IPTS 
Issue: Advances In the field of biotechnology are making it possible to determine and 
manipulate some of the genetic material of human cells for medical purposes. The 
Human Genome Project has opened a wider door to these possibilities, providing 
scientists with the data and tools needed to identify and understand the basis of genetic 
diseases and disorders, together with other inherited traits, while also foreshadowing 
difficult ethical controversies. 
Relevance: Within the European Union ethical issues concerning the application of the 
growing knowledge of human genetics are being approached differently from one 
country to another according to the different philosophical and moral attitudes in the 
Member States. Since the future application of gene technology in medicine will concern 
every citizen in Europe, these topics have to be discussed in a way that involves the 
public to ensure transparency and trust in political decisions. More so as the 
development of a common view on ethical issues throughout Europe might be 
necessary. The design of a European Research Area includes an "area of shared values" 
and recognizes as well the need to further the dialogue between science and society. 
introduction 
A part from environmental factors, it is a person's genome (the entire genetic ma­terial that is present in each cell of the body) that determines his/her health and 
susceptibility to diseases. The genetic material of an 
individual is contained in the nucleus of each cell 
in the form of chromosomes (46 chromosomes in 
23 pairs, each set derived from one parent). The 
chromosomes contain the genetic material, the 
DNA, which consists of 4 different building blocks, 
the nucleotide bases. The sequence of these nu­
cleotide bases within the DNA molecule constitu­
tes the genetic information. The sequence that 
codes for one single protein is called a gene. The 
human genome consists of around 3 billion bases 
and approximately 100,000 genes. Changes in the 
number and structure of chromosomes can lead to 
severe disorders, but small changes in the sequence 
of the nucleotide bases can also cause disease. 
Developments in genetic research and gene 
technology have elucidated possible genetic causes 
of known hereditary diseases and have made it 
possible to diagnose and influence a person's 
genetic makeup. The main areas of application of 
gene technology for medical use are genetic testing 
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(for diagnostic purposes), gene therapy at somatic 
and germ cell level and, most recently discussed, 
the therapeutic cloning of embryo stem cells for 
developing specialized tissue. 
Genetic testing 
The analysis of structural chromosome aberra-
tions, which for example cause Down's syndrome 
(3 copies of chromosome 21 instead of 2), is well 
known and has been in use since the 1960s (cyto-
genic investigations). The rapid progress in molecu-
lar genetics and the development of new techni-
ques has made possible the direct analysis of the 
DNA and the development of tests for mutations 
in genes which might be responsible for certain 
diseases as cystic fibrosis, Huntington's disease 
and sickle-cell anaemia, and also for arthritis and 
cancer, which are clearly influenced additionally 
by environmental factors. The ongoing Human 
Genome Project will provide more information on 
the underlying genetic causes of several diseases 
and will push the development of respective tests. 
Genetic tests have a number of actual and 
potential uses: 
• Broadening the diagnostic repertoire to detect 
or verify the cause of unclear symptoms (e.g. 
cystic fibrosis, Huntington's disease). 
• Predicting possible future onsets of diseases. 
Prenatal diagnosis includes cytogenic analysis 
and molecular genetic testing of the foetus. The 
first is routinely applied in the case of 
pregnancies in older women. Chromosomes 
are examined for microscopically visible ma-
cromolecular aberrations. Molecular genetic 
tests are used to determine whether the em-
bryo carries certain mutations within a gene 
that are responsible for hereditary diseases. In 
the case of in vitro fertilization the early em-
bryonic cells can be examined via preimplan-
tation diagnosis before the embryo is implan-
ted into the uterus. Preclinical diagnosis is 
applied after birth before any symptoms of a 
hereditary disease are recognizable. Persons 
can be tested for carrying genetic mutations and 
thus information obtained about future health. 
Predisposition diagnosis can be used to deter-
mine the personal risk for certain multifactorial 
diseases like, for example, coronary heart di-
sease. Persons affected will be able to change 
their lifestyle according to the diagnosis and 
thus reduce their risk of developing the disease. 
These and other tests will be developed in the 
future, building on the expanding knowledge of 
the human genome. 
• Customizing medical treatment for each patient. 
Some patients may not respond to drugs to 
which others respond very well,'or even have 
adverse reactions to these treatments. Pharma-
cogenomical research is trying to correlate the 
genetic makeup of individuals with their 
response to different medicines. The aim is to 
find "the right medicine for the right patient" to 
make treatment more effective in future. 
Today genetic tests are available for about 100 
hereditary diseases. These tests are mainly used 
for predictive, i.e. prenatal or presymptomatic, 
purposes. The information obtained differs in 
many ways from conventional diagnostic tests, 
thus raising new issues. 
Quality of genetic tests 
Because of the far-reaching consequences of 
genetic test results, the quality of genetic testing 
services and the reliability of the results are 
fundamental prerequisites for the application of 
this technique. Genetic testing is becoming 
increasingly frequent, tests being offered not only 
by specialized hospitals but also by analytical 
laboratories and these tests are sometimes offered 
directly to the patient. Currently, there are no 
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common European regulations ensuring minimum 
standards of the services provided (e.g. in terms 
of technical equipment, technical training of 
laboratory staff, accurate interpretation of results 
and provision of sufficient information to users, 
reliability of the results, and pre- and postanalytic 
counselling (Dequeker & Cassiman, 1998)). 
Recognizing the need to ensure test quality and 
consumer protection concerning genetic testing on 
a European level, the IPTS organized a workshop in 
July 2000 with all the main stakeholders to discuss 
possible ways of achieving this. Additionally the 
OECD is active in fostering appropriate and 
harmonized approaches for dealing with genetic 
testing on an international level. 
Ethical aspects of genetic testing 
In the case of prenatal testing the question of 
sparing children from future suffering because of a 
severe hereditary disease has to be weighed against 
the question as to whether we, as a society, have 
the right to decide which lives are worth living. In 
the case of preimplantation diagnostics the possi-
bility of choosing between different embryos arises 
and with it the possibility of abuse and "positive 
eugenics" (selecting the gender and in future per-
haps certain characteristics to get a "quality child"). 
The ability to select embryos according to their 
genotype might in the future create social pressure 
on parents who have disabled or ill children ("no-
wadays this is avoidable and therefore it should not 
happen") and a changing acceptance for han-
dicapped persons. 
Another ethical question connected with 
preimplantation diagnostics is the use of toti-
potent embryo cells for a biopsy and embryo 
selection. This technique destroys these cells, 
which have the potential to develop into human 
beings and are thus regarded as having the same 
status as embryos, which have to be protected. 
Preimplantation diagnosis is not allowed in 
Germany, Portugal, Austria and Switzerland. 
A person's knowing that they carry the genes 
for a hereditary disease, which will perhaps not 
show its first symptoms within the next 10 or 20 
years, is a heavy psychological burden, even more 
so when there is no expectation of therapy. On the 
other hand, this knowledge can enable the 
affected person to arrange the remaining period of 
his/her healthy life accordingly. In contrast to 
conventional diagnosis, the genetic test result not 
only affects the person tested, but also family 
members, who could carry the respective gene(s) 
too and who may or may not want to have any 
information about their risk of future disease. 
With the possibility of predicting potential 
risks of suffering from a disease in the future, the 
question of ownership and confidentiality/accessi-
bility of genetic data arises. Especially in the con-
text of health insurance and employment there is 
a danger of discrimination. Insurance companies 
might refuse to sell life or health insurance to 
high-risk individuals or charge much higher 
premiums. On the other hand, people who can 
provide proof of a clean genetic history can be 
offered much cheaper contracts. However 
insurance companies themselves might also 
experience problems if there is no obligation to 
disclose risk factors for genetic disease. For 
instance, people who know that they will develop 
a serious disease could buy extra insurance cover, 
whereas people who know they have only a small 
risk could decide to buy less insurance. This 
distortion would drive up premiums and could 
undermine the health insurance market. To 
counter this risk, in October 2000 insurance 
companies in Great Britain obtained permission 
to ask for genetic tests results. So far, the 
Department of Health's genetics and insurance 
committee has approved only a test for Huntin-
gton's disease, but others will certainly follow. In 
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contrast, in most other countries the use of genetic 
information by insurers is restricted or even 
prohibited. 
As regards the effects of genetic testing on the 
job market, employers prefer workers who are less 
likely to become ill, because this reduces the costs 
of replacement and retraining, interruptions in 
production and insurance. Moreover, some work 
environments may be known to predispose 
workers to a high rate of certain illnesses, and 
employers might prefer to hire workers who are 
genetically resistant rather than susceptible to 
these particular environment-related illnesses. 
Employers might hire only those who submit 
genetic data or offer lower wages and salaries to 
applicants who do not submit it. 
Gene therapy 
The aim of gene therapy is to change the 
expression of some genes in an attempt to treat, 
cure, or ultimately prevent disease (Anderson, 
1998). Current gene therapy is primarily experi-
mental, with only a few human clinical trials under 
way. Gene therapy can be targeted to somatic 
(body) or germ (egg and sperm) cells. 
Somatic level gene therapy 
In somatic gene therapy, the genome of certain 
cells of the individual undergoing therapy is 
changed, but the change is not passed down to 
the next generation. The use of gene therapy to 
cure a disease at the somatic level has no moral 
drawbacks as long as the ethics of patient safety 
and other aspects that apply to any new therapy, 
regardless of its nature, are maintained. 
In the early years of gene therapy, the focus 
laid entirely on treating diseases caused by single-
gene defects such as haemophilia, Duchenne's 
muscular dystrophy, cystic fibrosis, and sickle cell 
anaemia. The main aim was to find ways to insert 
the correct gene to substitute for the disease-
carrying one. In the late 1980s and early 1990s, 
the concept of gene therapy expanded to some 
acquired diseases. More recently, the use of gene 
therapy is aiming not necessarily to treat a disease 
but as an alternative way to deliver proteins. It is 
already possible to use gene transfer technologies 
to enhance the immune systems of advanced 
cancer and HIV-infected patients or to promote 
revascularization of ischaemic tissue in coronary 
artery disease and peripheral vascular disease. 
Gene therapy is still in the preliminary stages, 
though some successes, especially in blood-cell-
related disorders, have been achieved. Very 
recently, immune response recovery in a type of 
inherited severe combined immunodeficiency 
(SCID) has been achieved by gene replacement in 
bone marrow stem cells using a retroviral vector 
(Cavazzana-Calvo, 2000). 
Ethical aspects of somatic gene therapy 
The main ethical problem that research on 
somatic gene therapy encounters is the fact that it 
inevitably involves human experimentation. The 
death of Jesse Gelsinger, the first tragedy ever made 
public in the history of gene therapy, set alarm bells 
ringing last year. The 18-year old boy had 
volunteered at the University of Pennsylvania in 
US, to help test a treatment for a rare metabolic 
disorder. He was injected with a disarmed virus 
carrying a correct copy of the gene that was 
defective in his own genome. The therapy ultima-
tely caused his death. Controversy was raised after 
the father of the boy found out about previous 
experiments carried out on monkeys that had also 
caused their death and about cases of liver toxicity 
in other human patients that underwent similar 
therapies. He had not been properly informed 
before his son participated in the trial. The need for 
clear protocols and informed consent (based on 
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knowledge of all the facts) from the patient is 
obvious. However, these are issues that come up in 
any research that requires testing on humans at 
some point, and are not specific to the field of 
genetics. The adoption of a new medical technique 
is typically preceded by extensive scientific studies 
to establish its safety and efficacy. In the case of 
new gene therapies, these requirements should not 
be any different. Other disputes may arise over the 
ethics of conducting investigations that entail 
experimenting on children and foetuses, and in the 
case of germ-line therapies, on human embryos. 
Germ cell level gene therapy 
In case of germ cell therapies, the target of 
genetic intervention is the germ cells, which are 
the cells containing the genetic information that 
will be passed on to the next generation. The fact 
that future descendants will inherit the changes 
makes the use of gene technology to erase a 
known genetic defect problematic. Up front, there 
is not.much to question: If it is known that a 
specific mutation, deletion or insertion in the 
DNA of an embryo could be changed so that the 
future baby does not develop a fatal disease or a 
disorder that will determine his/her well-being 
(blindness, life in a wheel-chair, etc)... should we 
not intervene? The answer seems obvious, 
intervention now is more efficient than repeating 
somatic gene therapy generation after generation, 
and even in utero somatic gene therapy is too late 
for some diseases. However, tampering with the 
germ line is seen by some as playing God and it 
may be something society is unwilling to tolerate. 
Ethical aspects of germ line 
gene therapy 
Though it is still not known how many non-
disease human characteristics are, at least in part, 
inherited, certain traits are substantially influen-
ced by a person's genome. Many of these traits 
probably result from the interaction of numerous 
individual genes with environmental factors. 
Altering the function of one of these genes may 
have undesired effects on other physical or mental 
characteristics. Eventually, however, research is 
likely to reveal techniques for successfully enhan-
cing these non-disease genetic traits. Germ line 
manipulation creates the possibility of genetic 
interventions to enhance non-disease traits, for 
example, to increase strength, stamina, and per-
haps even intelligence. Where do we draw the 
line? What traits are going to be enhanced? 
Clearly, it would be a great achievement if a child 
is definitively cured of cystic fibrosis or a parti-
cular family line is liberated from the burden of 
fragile X syndrome or any other inherited disorder. 
However, to many, eliminating genetic defects is 
dangerously close to "eugenics", the genetic im-
provement of the human race. 
Apart from the fear of misuse of these techni-
ques for unpalatable eugenic goals, there are also 
technical uncertainties about their long-term 
effects. Some people fear that germline gene the-
rapy could go horribly wrong in unexpected ways 
and that irrevocable mistakes could show up 
generations later. Some genetic defects have prevai-
led because at the same time they produced a flaw, 
they conferred some type of protection against, for 
example, specific infections. Eliminating specific 
sequences from the population may therefore have 
unforeseen consequences. 
Stem cells 
Stem cells are cells that have the ability to 
divide for indefinite periods in culture and to give 
rise to specialized cells. Cells only become mortal 
after they become specialized into different tissue-
types. Human development begins when a sperm 
fertilizes an egg and creates a single cell that has 
the potential to form an entire organism. Very 
soon after fertilization, this cell divides into 
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identical cells with the potential to develop into 
any kind of tissue, known as stem cells. As the 
embryo grows into a foetus and the cells develop, 
they specialize and lose this potential. Stem cells 
can also be found in some types of adult tissue. In 
fact, stem cells are needed to replenish the supply 
of the cells in our body that normally wear out. 
However, it is believed that the potential of adult 
stem cells to grow into any type of tissue is not 
comparable to that of embryonic stem cells and 
this is one of the main reasons to pursue research 
using cells from embryos, not just from adults. 
Stem cells will have an increasing role in 
health care. At the most fundamental level, stem 
cells could help us to understand the complex 
events that occur during human development, the 
genetic signals of tissue/cell specialization. 
Cancer, many birth defects and other pathological 
conditions are due to abnormal cell specialization 
and cell division. A better understanding of these 
processes will help prevent the errors that cause 
these pathologies. 
Human stem cell research could also 
dramatically change the developing and testing of 
new drugs. New pharmaceuticals could be tested 
using specialized human cell lines, which would 
shorten the time required for testing. 
The most interesting and, at the same time, the 
most controversial potential application of human 
stem cells is the generation of cells and tissue that 
could be used for transplantation instead of 
donated organs and tissues. This would solve the 
current need for organs available for transplan-
tation given that demand for organs constantly 
outstrips supply. Stem cells, stimulated to develop 
into specialized cells, offer the possibility of a 
renewable source of replacement cells and tissue 
to treat a large number of diseases (Parkinson's 
and Alzheimer's diseases, spinal cord injury, heart 
failure, stroke, burns, heart disease, diabetes, 
arthritis, etc). All this is as yet unachievable but 
research is advancing steadily, firstly, towards 
understanding the cellular events that lead to cell 
specialization in humans (to direct these stem 
cells to become the types of tissue needed for 
transplantation) and secondly, towards overco-
ming the problem of immune rejection. Because 
human stem cells derived from embryos or foetal 
tissue would be genetically different from the 
recipient, they would be subject to rejection. Here 
is where genetics enters into play trying to solve 
this problem. The use of somatic cell nuclear 
transfer (SCNT) would overcome the incompa-
tibility issue. In SCNT, the nucleus of a somatic 
cell from the patient is fused with a donor egg cell 
from which the nucleus has been removed. With 
proper stimulation the cell would develop into an 
embryo which would produce ste'm cells that 
could then be stimulated to develop into the tissue 
needed for transplantation. Because most of the 
genetic information is contained in the nucleus, 
these cells would be essentially identical to the 
patient's so they would not, at least in theory, 
produce an immune reaction when transplanted. 
There is a major ethical concern in using this 
technique since, if carried all the way through to 
development, it could produce individuals with 
the same genetic information. This would then be 
what is generally understood as human cloning 
(Figure 1). 
Ethical aspects of stem celi 
genetic research 
Ethics commissions in several countries have 
already approved research on the human embryo 
as long as is done before the 14th day of develop-
ment, while the brain and spinal column of the 
embryo have not yet become differentiated. Using 
unused embryos from the residual production from 
in vitro fertilization has been approved in many 
instances, but the possibility of applying cloning 
techniques and creating new human embryos as 
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Human cloning 
part of research has sparked off a great deal of 
controversy. While cloning techniques not related to 
human reproduction might provide effective medi­
cal tools, there are objections to them on the 
grounds that generating human embryos for re­
search could pave the way for reproductive cloning. 
In August 2000, the US National Institutes of 
Health (NIH) released guidelines for NIH funded 
research using human stem cells derived from 
human embryos or foetal tissue. For studies using 
cells derived from human embryos, NIH funds 
may be used only if the cells were derived from 
frozen embryos that were created for the purposes 
of fertility treatment and were surplus to clinical 
needs. Also in August 2000, the British Govern­
ment decided to ask the Parliament to approve 
human embryo cloning for therapeutic purposes, 
this is one step further towards the use of human 
embryos for research, although cloning for repro­
ductive purposes will remain prohibited. This pro­
posal was based on a report by the British Ministry 
for Health which recommended allowing 
research involving human embryos for the purpose 
of developing tissues from embryonic stem cells 
to treat diseases and the use of SCNT for produ­
cing stem cells for cell and tissue therapy. This 
generated debate in the European Union (EU). The 
European Parliament (EP) responded to this 
controversy with the adoption of a communi­
cation mentioning that therapeutic cloning, which 
involves the creation of human embryos for 
research purposes, poses a profound ethical dilem­
ma, it implies reaching a point of no return in the 
field of research and is contrary to the policy 
adopted by the EU. The EP invited the British 
government to review its position on the cloning 
of human embryos and the members of the British 
Parliament to reject the controversial proposal. 
The European Commission (EC) cannot take 
any legal action because Member States under the 
EU Treaty retain full prerogative to legislate on 
ethical matters. In fact, legislation differs widely 
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between Member States, reflecting a diversity of 
positions on the issue. However, Community 
action on biotechnological research is based 
increasingly on the most rigorous ethical princi­
ples. The Fifth Framework Programme (FP5) on 
Research and Technological Development (1998­
2002) excludes projects involving the cloning of 
human embryos for reproductive Innovation 
Technology purposes from funding. No research 
projects on therapeutic cloning are currently 
being funded, although financial support is being 
given to bioethical research projects on the 
potential risks and benefits of cloning technology. 
The FP5 also finances complementary approaches 
aimed at developing new cell therapy techniques, 
particularly on the basis of cell differentiation. 
Community research is scrutinized by the 
European Group on Ethics in Science and New 
Technologies1 (EGE) that was set up in January 
1998 to help the EU internal market to operate in 
accordance with Europe's ethical values. 
A common European debate on the 
ethical evaluation of research 
The rapid development of science is creating a 
major challenge for society. The ethical evaluation 
of the possible impacts of the research in the field 
of genetics may be too great a burden for policy­
makers, even if they rely on scientific, technical 
and ethical advisors in the decision­making pro­
cess. Society at large may also need to play a bigger 
role than it has been accustomed to. The dialogue 
between science and society needs to be more 
fluent, as shown in the latest Eurobarometer study 
"The Europeans and biotechnology" (Eurobaro­
meter 52.1 ). In this study only 11 % of the popula­
tion in the EU (13% men and 9% women) feel they 
are adequately informed about biotechnology 
though up to 41% of them would be willing to 
participate in public debates or hearings con­
cerning biotechnology. Society needs to be better 
informed for the obvious reasons of public trust and 
transparency but additionally because it needs to 
involve itself in the ethical evaluation of scientific 
research. Especially in areas like human genetics 
where the implications are so significant, decisions 
should be taken with the participation of all stake­
holders. The research community needs to ack­
nowledge to society the moral and social conse­
quences of their work. Science is no longer 
considered morally neutral and the control of 
technological advances is not exclusively left to the 
"experts", as it was in the past. These evaluations go 
beyond the technical aspects of research and enter 
grounds of purely ethical responsibility. Society 
wants to participate actively in regulating those 
procedures and techniques which have a powerful 
impact on the present and future of humanity. Just 
delegating the task of defining research and 
development policies to public and private 
research institutions is perceived as being 
inadequate. Channels of citizen participation need 
to be improved and the public needs to be better 
informed on scientific matters. 
In the case of the EU, one major step towards 
achieving this objective of societal involvement has 
been built into the design of the future European 
Research Area2 (ERA). In its communication of 
January 2000 about the ERA, the European Commi­
ssion states its aim to develop a shared vision of 
ethical issues of science and technology and to 
foster a coherent approach to these issues. In the 
"First Step towards a European Research Area" 
document (2000­48.EN), the Commission lays 
down the initial action plan for the implementation 
of the ERA, concentrating first on the priorities set 
by the European Council. Among these priorities, 
the Commission is planning several communi­
cations, one of them, set for the beginning of 2001, 
on the social and ethical aspects of research in 
Europe. One of the Commission's approaches to 
handling these ethical problems arising from scien­
ce and technology is to promote a clear statement 
of the values shared by Europeans. _ J | 
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Ethical assessment of Life science 
research proj ects 
Laurence Cordier, European Commission 
introduction 
he European Commission has supported 
research in the area of the Life Sciences, 
medicine and biotechnology for many 
years now. It is the responsibility of a 
funding institution to promote the highest ethical 
standards and to make sure that it supports research 
that is performed in a responsible manner. 
This principle is embodied in the article 7 of 
the Fifth framework programme for research, 
technological development and demonstration 
activities1 which reads: 
"All research conducted pursuant to the Fifth 
Framework programme shall be carried out in 
compliance with fundamental ethical principles 
including animal welfare requirements, in confor­
mity with Community law." 
In its opinion no. 10 on the Fifth framework 
programme, the European Group on Ethics (EGE)2 
has given the Commission some guidance on how 
one should deal with ethical aspects of the 5 l" 
Framework programme. Accordingly, for the 
implementation of the programme "Quality of Life 
and management of Living resources"3 in particular, 
a systematic ethical assessment of issues arising 
from projects has been organized. This article fur­
ther describes how the Commission services orga­
nized the ethical assessment of projects submitted 
for funding in the area of the Life sciences. 
Proposal submission 
The "Quality of Life" programme imposes spe­
cific requirements on all proposers concerning 
ethical issues. Proposers have to describe the 
ethical issues arising from the research they intend 
to conduct in their proposals. They should specify 
whether the project involves research involving 
human beings, use of human embryos, use of 
human tissues, use of personal data or genetic 
information, and whether the research involves the 
use of non­human primates or other animals. 
Proposers also have to describe the measures taken 
to address the ethical issues that emerge. 
Scientific evaluation 
In the first instance all proposals for research 
which are submitted undergo a thorough scientific 
evaluation during which a first assessment of the 
ethical Issues is made. For example the evaluators 
indicate if they believe that in some projects ethical 
issues are not addressed by the proposers in a 
satisfactory manner. 
Ethical review and the report 
An ethical review is performed only for projects 
that have already been selected for funding and 
which raise serious and/or controversial issues, 
such as research using foetal and embryonic 
tissues, or research involving non­human primates. 
In addition, special attention is also paid to projects 
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involving persons unable to give a valid consent 
(including children) or clinical trials performed out-
side the Member states, and research using per-
sonal data and genetic data. 
The main difficulty in assessing ethical issues at 
a European level instead of at a more local level is 
the question of the reference documents. What rules 
and ethical principles should serve as a reference? 
In addition to international guidelines such as 
the Declaration of Helsinki, the Convention on 
Human Rights and Biomedicine4, the ethical 
review is following the guidance of the different 
opinions of the European Group on Ethics, for 
example the opinion on "research involving the use 
of human embryo in the context of the 5 tn Fra-
mework programme" and the opinion on "human 
tissue banking". 
involving non-human primates and clinical trials 
on human beings. Therefore the range of compe-
tencies within the panel must be very wide. 
Negotiation 
The ethical review panel 
The review is performed by a panel of 
independent experts from various disciplines 
representing different societal interests (such as 
animal protection groups, patient organizations, 
industry, etc.) Of course experts should also be 
coming from different Member states to represent 
the different cultures present in Europe. 
A variety of issues are covered by the review, 
ranging for example, from vaccine trials to use of 
human embryonic tissues. The same panel may re-
view the use of animals and, in particular, projects 
The reports of the ethical review panel will be 
transmitted to the coordinators of the projects at 
the time of the contract negotiations. The panel's 
recommendations have to be taken into account 
by participants before the contract is signed. The 
technical annex must be amended accordingly. 
Finally, copies of panel opinions/approvals have 
to be forwarded to the Commission. 
Conclusion 
The ethical assessment of life science research 
proposals that is organized by the Commission 
services is not in any way replacing the ethical 
review of research that is performed at national or 
local level. Participants in research projects must 
in any case conform to their national regulations 
and their codes of practices, which may require 
an ethical review and/or a prior authorization. 
Through the ethical assessment of research 
proposals submitted for funding the intention is to 
show the whole European research community 
that ethical issues have to be dealt with according 
to the highest standard of protection for human 
beings and animals. The overall aim is that it 
remain clear that EC funded research in Life 
science is conducted in a responsible way. 
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Teaching Science, Teaching the 
Responsible Conduct of Research 
Rache l le D. Ho l l ande r , NSF 
Introduction 
he time is long past since teaching staff and 
others with responsibility for educating, 
training and supervising researchers should 
be including formal training in the res-
ponsible conduct of research in those efforts. In 
1997, the regions of Asia, Western Europe, and the 
Americas (where statistics are available) granted 
159,235 doctoral degrees in all fields of science 
and engineering. Standing at the peak of a large 
educational enterprise that represents a major 
social investment, the numbers indicate the 
changed context in which post-graduate education 
operates. 
Given the scale of these investments, and the 
importance to society of results from research acti-
vities that involve post-graduate and post-doctoral 
assistance, it is not surprising that questions arise 
concerning the roles and responsibilities of post-
graduates, post-doctoral associates, teaching staff, 
and their institutions. Tighter coupling between 
academic and other social institutions has 
prompted increased attention to ethical aspects of 
the relationships between established and trainee 
researchers. The system is showing the strains of 
increasing numbers as well as increasing calls for 
accountability from post-graduate students them-
selves and the governmental funders and sponsors 
of post-graduate education. Adequate response to 
these stresses requires the attention of academic 
institutions and professional associations. Most 
important, perhaps, are the responses at the level 
of departments and programmes actually produ-
cing new PhDs. 
A particular impetus for change in this arena 
has been increased social and governmental 
attention to questions of research misconduct. 
These concerns resulted in new regulations in the 
US that require institutions to have procedures in 
place that respond to allegations; many other 
nations have implemented procedures to respond 
to this concern. Governmental and academic 
institutions as well as scientific and professional 
associations regard this as a broader mandate 
for education in research integrity. In the US, the 
National Institutes of Health has established 
requirements for ethics training for all research 
staff that have implications for training, mento-
ring, and supervision. 
Professional associations have been custodians 
of good practice for their members as well as for 
practitioners and researchers who may not be 
members but draw on the body of knowledge and 
relevant expertise that these associations 
incorporate. Today's world requires that experts 
work with others with very different specialities 
more often than in the past; the need for these 
group or team efforts raises additional issues for 
good training, mentoring, and supervision, as well 
as for the effective review of research results. 
% 
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For persons in academic research environ-
ments to do the right thing, they require and 
deserve assurance that others will do their share, 
and that they will be protected if difficulties arise. 
To foster this ethic, post-graduate departments or 
groups should develop adequate written state-
ments of the terms of post-graduate study, inclu-
ding policies about conflict of interest and training 
in the responsible conduct of research, and assign 
necessary duties to individual teaching staff 
members. Such statements should be distributed 
to trainees. Individual members of teaching staff 
often have responsibilities in admitting students; 
similarly, they can assume responsibilities in 
advising students, post-doctoral associates, and 
new staff, and in placing graduate students in 
postdoctoral positions and jobs. Tasks that can 
help post-graduate students and post-doctoral 
associates succeed - such activities as writing 
proposals or research reports - can also be par-
celled out among staff, as can assignments for ma-
king students aware of ethical aspects of research 
and professional activities. 
To do a good job, mentors and trainees need to 
be educated in the research standards of their 
fields. An approach to this subject area would be 
expected to incorporate attention to foundational 
principles and concepts with which issues 
particular to the field or fields of study can be 
examined. The curriculum would examine issues 
of ethical conduct in scientific research, and 
professional behaviour, recognizing the influence 
of organizational and social contexts on problem 
definition and response capabilities. Cases would 
provide illustrations of problems and better and 
worse approaches to their resolution. They should 
give students opportunities to develop their analy-
tical skills and emotional understanding of the 
situations in which they have to operate. They can 
also provide insight into social perceptions of the 
influence of research and technology on social 
welfare and justice. 
As parts of the core of such curricula, students 
need to be familiar with the relevant codes of 
ethics. In experimental work, standards of labo-
ratory practice or laboratory safety need to be 
discussed; and the same is true for standards of 
fieldwork and survey practice. Regulatory require-
ments concerning animal and human subjects 
need to be well understood. Besides the important 
area of potential harms, standards for ethical 
practice of human subjects research include 
matters of privacy and confidentiality, consent, and 
community protection. In research in the social and 
behavioural sciences, complex questions concer-
ning deception or stigmatization of individuals or 
communities may need particular care, particular-
ly in the context of research on vulnerable popu-
lations, in other cultures, or involving deception. 
All teaching staff and trainee researchers should 
be familiar with definitions of research miscon-
duct and the policies of their programme and 
institution. Responsible use of statistical methods, 
where appropriate, needs to be understood, as do 
requirements for stewardship of records and data 
and ownership of ideas and intellectual property. 
Standards for responsible authorship and peer 
review also need to be understood, and the 
discrepancies that may exist between different 
fields need to be examined. These are areas where 
departments and institutions as well as professio-
nal associations and scientific societies can have 
much to offer. 
A broader and deeper approach to research 
ethics might examine the normative consequences 
of social commitment to innovation. This approach 
would encourage students and staff to examine 
processes and outcomes for setting research prio-
rities as well as ethical dimensions inherent in and 
consequent to research outcomes and technolo-
gical applications. 
In conclusion, programmes and departments 
should create systems that specify the duties of staff 
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involved in research ethics training, and describe 
how their performance should be evaluated. 
Recent publications and guidance from national 
bodies and professional associations, as well as 
books and articles by individual scholars, can be 
helpful in developing materials and activities on 
research ethics that are responsive to the needs of 
new post-graduate students and members of the 
teaching and research staff. Training for teaching 
staff and advisors, as well as curriculum deve-
lopment activities, will be needed. One of the side 
benefits of increased attention to structural 
reforms and ethical research practice in post-
graduate education might be expansion of 
researchers' capabilities to exercise responsible 
social leadership. J_F 
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The Joint Research Centre (JRC), one of the Directorates General of the European Commission, 
carries out research and provides technical know­how in support of European Union (EU) policies. 
Its status as a Commission service, which guarantees independence from private or national 
interest, is crucial for pursuing this role. 
The JRC implements its mission through specific research programmes decided by the Council 
upon advice from the European Parliament falling under the European Union Framework 
Programmes for research and technological development. The work is funded by the Budget of the 
European Union with additional funding from associated countries. The work of the JRC includes 
customer­driven scientific and technical services for specific Community policies, such as those on 
the environment, agriculture or nuclear safety. It is involved in competitive activities in order to 
validate its expertise and increase its know­how in core competencies. Its guiding line is that of 
"adding value" where appropriate, rather than competing directly with establishments in the 
Member States. 
The JRC has eight institutes, located on five separate sites, in Belgium, Germany, Italy, the 
Netherlands and Spain. Each has its own focus of expertise. 
The Institutes are: 
• The Institute for Reference Materials and Measurements (IRMM) 
• The Institute for Transuranium Elements (ITU) 
• The Institute for Advanced Materials (1AM) 
• The Institute for Systems, Informatics and Safety (ISIS) 
• The Environment Institute (El) 
• The Space Applications Institute (El) 
• The Institute for Health and Consumer Protection (IHCP) 
• The Institute for Prospective Technological Studies (IPTS) 
Further information can be found on the JRC web site: 
www.jrc.cec.eu.int 
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A B O U T T H E I P T S 
The Institute for Prospective Technological Studies (IPTS) is one of the eight institutes making up the 
Joint Research Centre (JRC) of the European Commission. It was established in Seville, Spain, in 
September 1994. 
The mission of the Institute is to provide techno-economic analysis support to European decision-
makers, by monitoring and analysing Science & Technology related developments, their cross-
sectoral impact, their inter-relationship in the socio-economic context and future policy 
implications and to present this information in a timely and integrated way. 
The IPTS is a unique public advisory body, independent from special national or commercial 
interests, closely associated with the EU policy-making process. In fact, most of the work 
undertaken by the IPTS is in response to direct requests from (or takes the form of long-term policy 
support on behalf of) the European Commission Directorate Generals, or European Parliament 
Committees. The IPTS also does work for Member States' governmental, academic or industrial 
organizations, though this represents a minor share of its total activities. 
Although particular emphasis is placed on key Science and Technology fields, especially those that 
have a driving role and even the potential to reshape our society, important efforts are devoted to 
improving the understanding of the complex interactions between technology, economy and 
society. Indeed, the impact of technology on society and, conversely, the way technological 
development is driven by societal changes, are highly relevant themes within the European 
decision-making context. 
The inter-disciplinary prospective approach adopted by the Institute is intended to provide 
European decision-makers with a deeper understanding of the emerging S/T issues, and it 
complements the activities undertaken by other Joint Research Centres institutes. 
The IPTS collects information about technological developments and their application in Europe 
and the world, analyses this information and transmits it in an accessible form to European 
decision-makers. This is implemented in three sectors of activity: 
• Technologies for Sustainable Development 
• Life Sciences / Information and Communication Technologies 
• Technology, Employment, Competitiveness and Society 
In order to implement its mission, the Institute develops appropriate contacts, awareness and skills 
for anticipating and following the agenda of the policy decision-makers. In addition to its own 
resources, the IPTS makes use of external Advisory Groups and operates a Network of European 
Institutes working in similar areas. These networking activities enable the IPTS to draw on a large 
pool of available expertise, while allowing a continuous process of external peer-review of the ¡n-
house activities. 
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The IPTS Report ¡s published in the first week of every month, except for the months of January and August. It is edited in English 
and is currently available at a price of 50 EURO per year in four languages: English, French, German and Spanish. 
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The European Science and Technology Observatory Network (ESTO): 
IPTS ­ JRC ­ European Commission 
W.T.C., Isla de la Cartuja s/n, E­41092, Sevilla, Spain 
tel.: +34­95­448 82 97; fax: +34­95­448 82 93; e­mail: ipts_secr@jrc.es 
ADIT ­ Agence pour la Diffusion de l'Information Technologique ­ F 
ARCS ­ Austrian Research Center Seibersdorf ­ AT 
CEST ­ Centre for Exploitation of Science and Technology ­ UK 
COTEC ­ Fundación para la Innovación Tecnológica ­ E 
DTU ­ University of Denmark, Unit of Technology Assessment ­ DK 
ENEA ­ Directorate Studies and Strategies ­ I 
INETI ­ Instituto Nacional de Engenharia e Technologia Industrial ­ Ρ 
ITAS ­ Institut für Technikfolgenabschätzung und Systemanalyse ­ D 
MERIT ­ Maastricht Economic Research Institute on Innovation and Technology ­ NL 
NUTEK ­ Department of Technology Policy Studies ­ S 
OST ­ Observatoire des Sciences et des Techniques ­ F 
PREST ­ Policy Research in Engineering, Science & Technology ­ UK 
SPRU ­ Science Policy Research Unit ­ UK 
TNO ­ Centre for Technology and Policy Studies ­ NL 
VDI­TZ ­ Technology Centre Future Technologies Division ­ D 
VITO ­ Flemish Institute for Technology Research ­ Β 
VTT ­ Group for Technology Studies ­ FIN 
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